Neuropeptide System Regulation of Prefrontal Cortex Circuitry: Implications for Neuropsychiatric Disorders

Sanne M. Casello, Rodolfo J. Flores, Hector E. Yarur, Huikun Wang, Monique Awanayi, Miguel A. Arenivar, Rosario B. Jaime-Lara, Hector Bravo-Rivera and Hugo A. Tejeda

Neuropeptides, a diverse class of signaling molecules in the nervous system, modulate various biological effects including membrane excitability, synaptic transmission and synaptogenesis, gene expression, and glial cell architecture and function. To date, most of what is known about neuropeptide action is limited to subcortical brain structures and tissue outside of the central nervous system. Thus, there is a knowledge gap in our understanding of neuropeptide function within cortical circuits. In this review, we provide a comprehensive overview of various families of neuropeptides and their cognate receptors that are expressed in the prefrontal cortex (PFC). Specifically, we highlight dynorphin, enkephalin, corticotropin-releasing factor, cholecystokinin, somatostatin, neuropeptide Y, and vasoactive intestinal peptide. Further, we review the implication of neuropeptide signaling in prefrontal cortical circuit function and use as potential therapeutic targets. Together, this review summarizes established knowledge and highlights unknowns of neuropeptide modulation of neural function underlying various biological effects while offering insights for future research. An increased emphasis in this area of study is necessary to elucidate basic principles of the diverse signaling molecules used in cortical circuits beyond fast excitatory and inhibitory transmitters as well as consider components of neuropeptide action in the PFC as a potential therapeutic target for neurological disorders. Therefore, this review not only sheds light on the importance of cortical neuropeptide studies, but also provides a comprehensive overview of neuropeptide action in the PFC to serve as a roadmap for future studies in this field.

Keywords: prefrontal cortex, dynorphin, enkephalin, corticotropin-releasing factor, cholecystokinin, somatostatin, neuropeptide Y, vasoactive intestinal peptide

INTRODUCTION

Neuropeptides are widely distributed in the central nervous system (CNS) where they regulate various biological effects (Herbert, 1993; van den Pol, 2012; Kash et al., 2015; Nusbaum et al., 2017; Castro and Bruchas, 2019; Brockway and Crowley, 2020; Eiden et al., 2020). Currently, most neuropeptide studies are constrained to subcortical brain structures and tissue outside of...
the CNS. With the increase in investigations centered on cortical and limbic circuit function underlying higher-order cognition processes, the gap in knowledge of neuropeptide function in cortical circuits has become increasingly apparent. Thus, an increased emphasis on research examining neuropeptide modulation of cortical circuits is needed, particularly as we seek to identify potential therapeutic targets for psychiatric disorders (Salío et al., 2006; Nassel, 2009; Hoyer and Bartfai, 2012; Crowley and Kash, 2015; Smith et al., 2019). In this review, we highlight established knowledge and unknowns of dynorphin, enkephalin, corticotropin-releasing hormone, cholecystokinin, somatostatin, neuropeptide Y (NPY), and vasoactive intestinal peptide (VIP) action in the prefrontal cortex (PFC). This particular set of neuropeptides was chosen to investigate because of their abundance in discrete cells and critical role in motivational and cognitive behaviors that are relevant to a plethora of psychiatric disorders. In turn, we discuss the role of these peptides in regulating executive function, affective behavior, and the role of cortical neuropeptide dysregulation in neuropsychiatric disorders. Changes in neuropeptide expression and action could play a direct role in cortical dysfunction underlying neuropsychiatric disorders as well as enact indirect and widespread effects that have profound implications for systems dysregulation. Leveraging knowledge of neuropeptide action in cortical circuits with insights to cortical circuit dysfunction can help develop more focused and effective treatments that lead to improved therapy (Poyner et al., 2000; Roth, 2019), irrespective if a specific neuropeptide is key to the etiology and/or maintenance of the disorder. Ultimately, we provide a comprehensive overview of neuropeptide action in the PFC by establishing knowns and unknowns, discussing the potential role of neuropeptides in neuropsychiatric disorders and animal models, and providing insights for future research.

Neuropeptides
Neuropeptides are small proteins, composed of 3–100 amino acid residues, encoded by over 70 genes (Snyder and Innis, 1979; Herbert, 1993; Salío et al., 2006; Burbach, 2011; van den Pol, 2012; Kash et al., 2015; Nusbaum et al., 2017; Castro and Bruchas, 2019; Brockway and Crowley, 2020; Eiden et al., 2020; Fricker et al., 2020). Like amino acid and monoamine neurotransmitters, neuropeptides are signaling molecules used by nerve cells to communicate with other neurons, glial cells, and peripheral cells (Gozes et al., 2001). Relative to other signaling molecules, the neuropeptide class is diverse, and is hypothesized to mediate communication across longer time scales and larger volumes leading to broad, long-lasting modulation of neural processes (Kim et al., 2017). Despite this diversity, all neuropeptides share certain key characteristics that govern their signaling: expression and biosynthesis in neurons and peripheral cells, regulated release, the ability to regulate neural function via actions with receptors and/or ion channels, and processing/degradation upon release to terminate and/or modify signaling (Burbach, 2011). In addition to expression in peripheral cells, gene expression and biosynthesis of neuropeptides is associated with neurons (Baraban and Tallent, 2004). Most excitatory and inhibitory neurons in the cortex show expression of neuropeptides or a neuropeptide binding G-protein coupled receptor (GPCR; Tasic et al., 2018; Smith et al., 2019). A recent single-cell RNA-seq study reporting neuropeptide and neuropeptide-selective GPCR expression patterns in mouse neocortical neurons suggest that neuropeptidergic networks may exist within cortical circuits (Smith et al., 2019). These, and the evolving number of publicly available single-cell RNA-seq and in situ hybridization data sets, such as those from the Allen Brain Institute, serve as valuable resources to identify putative peptide-expressing brain regions and/or cell types.

Upon translation, neuropeptide precursor proteins undergo proteolytic processing, an activity dependent process controlled by intracellular calcium, that produces active neuropeptides (Hallberg, 2015; Hook et al., 2018; Fricker et al., 2020; Lee and Fields, 2021). Precursor proteins can yield a single neuropeptide, multiple distinct neuropeptides, and/or multiple copies of a single neuropeptide. A single precursor peptide giving rise to multiple copies of the same or related peptide is energetically advantageous and a means for signal amplification (Salío et al., 2006; Li and Kim, 2008; Hook et al., 2018; Fricker et al., 2020). This translational step results in unique families of related neuropeptides with similar physiological function (Hook et al., 2018) and is the first step toward the regulated secretory pathway, another key characteristic that neuropeptides share.

Neuropeptides are stored and released from dense core vesicles (DCVs) which are larger than the small, clear synaptic vesicles (SVs) and small to intermediate-sized vesicles that store and release amino acid and monoaminergic neurotransmitters, respectively (Martin, 1994; Kim et al., 2006; Russo, 2017). DCVs and SVs are differentially sensitive to stimuli that trigger exocytosis. Specifically, they may recruit different Ca$^{2+}$ sensors, allowing for independent regulation of exocytosis in a temporally- and activity-dependent manner (Zhang et al., 2011; Sudhof, 2012; Kim et al., 2017). Neuropeptide release from DCVs is triggered by small elevations in the Ca$^{2+}$ concentration in the cytoplasm, whereas secretion of amino acids from SVs requires higher elevations, as produced in the vicinity of Ca$^{2+}$ channels near the active zone at synapses (Hokfelt et al., 2000; Tallent, 2008; Nusbaum et al., 2017). These variations in DCV and SV sensitivity to exocytosis triggering stimuli may be important for dictating where neuropeptides are capable of being released. Specifically, SVs aggregate near regions on the presynaptic membrane containing release sites, where DCVs are more randomly distributed throughout the cell (Bean et al., 1994). However, nuanced organization of DCV clustering may exist that has yet to be revealed as studies have shown DCVs containing neuropeptides near dopamine receptors (Svingos et al., 1999), in close proximity to release sites (Song et al., 2020), or away from the active zone (Liguz-Lecznar et al., 2016). This indicates not only that DCVs can be released at multiple sites, but also that various combinations of expression and release patterns exist (Chini et al., 2017). Relative to fast neurotransmitters that bind to their cognate receptors with low affinity, neuropeptides bind with high affinity to GPCRs (Tallent, 2008; Burbach, 2011). It is important to note that following release, regulatory proteases can act on neuropeptides to modify their bioactivity. These modifications can cause inactivation, decrease or increase affinity.
for GPCR targets, or even confer selectivity for GPCR or ion channels beyond the initial GPCR targets (Mentlein, 2004; Hook et al., 2018). In summary, both the increase in sensitivity and variation in location of DCVs leads to neuropeptide signaling properties that shape circuit activity in a spatially- and temporally- distinct manner relative to fast transmitters.

**G-Protein Coupled Receptors**

When released from their DCVs, neuropeptides bind to their cognate GPCRs to initiate signaling. These receptors constitute the largest family of transmembrane proteins and mediate cellular responses to hormones, neurotransmitters, and neuropeptides through interaction with their extracellular loop binding pockets (Rosenbaum et al., 2009; Heldin et al., 2016). Some neuropeptides exhibit a high degree of promiscuity across GPCRs and can bind several receptor subtypes (Devi, 2001; Hoyer and Bartfai, 2012; Hook et al., 2018). Importantly, GPCRs are the therapeutic target of 34% of FDA-approved medications, highlighting the importance of neuromodulatory systems (Roth, 2019). Although the GPCRs we discuss in this review bind to endogenous neuropeptides that have been identified and characterized, it is important to note many GPCRs have not yet been linked to endogenous ligands and are designated as orphan GPCRs (Tang et al., 2012). Conversely, many neuropeptides have been described and it is unclear what the repertoire of GPCR activation is for these peptides [i.e., cocaine and amphetamine related transcript peptide (CART)]. Neuropeptides interact with proximal G proteins and other GPCR-associated signaling molecules, except in instances where neuropeptide release sites and receptor location are mismatched or not proximally located (Herkenham, 1987). Nevertheless, neuropeptides can bind distal G-protein and receptor sites via volume transmission (van den Pol, 2012). G proteins are heterotrimeric, specialized proteins comprised of an alpha, beta, and gamma subunit (Weis and Kobilka, 2018; Wooten et al., 2018). Upon agonist-induced activation of the GPCR, GDP is exchanged with GTP on the alpha subunit to initiate G-protein-mediated signaling and the separation of the alpha subunit and beta-gamma dimer (Bruchas and Chavkin, 2010; Burbach, 2011; Weis and Kobilka, 2018; Wooten et al., 2018; Lemos Duarte and Devi, 2020; Zastrow and Sorkin, 2021). Subsequently, each subunit interacts with secondary transducers that amplify signaling cascades or impact the function of regulators of intrinsic excitability or synaptic transmission, such as voltage-gated or ligand-gated ion channels. GPCR function and signaling is not limited to the plasma membrane, however, even after internalization GPCRs can continue to signal from endosomes (Zastrow and Sorkin, 2021). There are four subcategories of GPCRs determined by their alpha-subunit: G<sub>q</sub>/<sub>11</sub>, G<sub>12</sub>/<sub>13</sub>, and G<sub>olf</sub> (Rosenbaum et al., 2009). Each subtype of G protein alpha subunit has different modulatory effects and enacts different signaling cascades. A simple but useful oversimplification is that G<sub>q</sub>, G<sub>12</sub>/<sub>13</sub>, and G<sub>olf</sub> are stimulatory whereas G<sub>11</sub>/<sub>13</sub> is inhibitory. G<sub>q</sub> activates the phospholipase C (PLC) pathway enacting critical second messengers that mediate calcium signaling. G<sub>11</sub> activates the formation of cyclic adenosine monophosphate (cAMP) and subsequently activation of the protein kinase A pathway. G<sub>11</sub>/<sub>13</sub>-coupled GPCRs inhibit cAMP formation and recruit G-protein coupled inwardly rectifying channels (GIRKs) or inhibit voltage-gated Ca<sup>2+</sup> channels to decrease intrinsic excitability. G<sub>11</sub>/<sub>13</sub> and G<sub>12</sub>/<sub>13</sub> and either have no effect on or inhibit the other signaling cascades. For example, a G protein-biased agonist may only activate the G-protein dependent signaling but result in minimal to no activation of β-arrestin-dependent cascades. Conversely, GRK/β-arrestin biased agonists preferentially activate MAP kinase signaling cascades while sparing or minimally impacting G-protein signaling. Thus, modulatory effects of neuropeptides through GPCR signaling are dependent on the pathways in which they enact.

**The Prefrontal Cortex**

A detailed description of prefrontocortical function and architecture is beyond the scope of this review. Therefore, we invite the reader to the following review articles for a more in depth look at cortical architecture and circuit function (Carlen, 2017; Fishell and Kepecs, 2020; Ibrahim et al., 2020; Le Merre et al., 2021; Murray and Fellows, 2021; Tejeda et al., 2021). In this review, we focus on aspects of cortical circuits directly relevant to understanding the role of the neuropeptides in the PFC.

Studies using rodents have established the PFC is subdivided into three categories including the dorsomedial PFC (dmPFC), ventromedial PFC (vmPFC), and ventrolateral PFC (vlPFC) (Le Merre et al., 2021). Each subdivision contains distinct cortical subregions that share connectivity and anatomical features (Carlen, 2017). These subregions include the anterior cingulate and dorsal prelimbic (of the dmPFC), infralimbic and ventral prelimbic PFC (of the vmPFC), and orbital frontal cortex (of the vlPFC and vlPFC). Corticofugal neurons are diverse and can be categorized according to different characteristics, including morphology, patterns of local and long-range connectivity, intrinsic physiology, type of fast neurotransmitter released, and in some cases the neuropeptides they express. The PFC is the brain region with the most connections to other brain regions (Carlen, 2017; Le Merre et al., 2021). Cortical excitatory projection neurons send efferents to a wide array of target brain regions, including limbic structures such as the amygdala, thalamus, multiple nodes of the basal ganglia including the striatum, hypothalamus, monoaminergic centers of the midbrain, and the periaqueductal gray area. Inputs to the PFC arise from various associative and primary sensory cortices, thalamus, hypothalamus, and monoaminergic centers of the midbrain, hindbrain, as well as limbic regions, including the amygdala and...
ventral hippocampus. Prefrontal cortical circuits also contain a plethora of inhibitory neurons, which serve to limit the activity of principal excitatory neuron and/or disinhibit them (Ferguson and Gao, 2018; Fishell and Kepecs, 2020; Wang et al., 2020). Classes of cortical neurons are differentially localized across cortical layers and extensively interconnected (Harris and Shepherd, 2015; Carlen, 2017; D’Souza and Burkhalter, 2017; Adesnik and Naka, 2018). Cortical circuits integrate these intracortical connections with subcortical connections and local circuit motifs embedded in the microcircuits process them (Harris and Shepherd, 2015). The laminar structure of the PFC is elaborate and neuron location within layers underlies function (D’Souza and Burkhalter, 2017). For instance, excitatory outputs of cortical circuits tend to have layer specificity (Adesnik and Naka, 2018). These circuit motifs regulate cortical processes in various ways including, signal amplification via recurrent excitatory connections, lateral inhibition via polysynaptic inhibition, generation and/or maintenance of circuit-wide oscillatory activity, and mechanisms for signal convergence and divergence. Despite decades of research and significant advances in knowledge of nuanced synaptic connectivity of cortical networks and microcircuits therein, there are still many unknowns regarding how information is processed beyond fast excitatory and inhibitory connections. Therefore, uncovering more about how the cortex is organized is necessary to understand the extent to which neuropeptides modulate circuit function and behavior.

**Neuropeptides in the Prefrontal Cortex**

In the present review, we propose that neuropeptides, in the PFC, act as specialized modalities of communication that convey cellular and synaptic specificity via integration of neuropeptide-producing neurons, enzymes that degrade them, and cells bearing cognate receptors to their specific neuropeptide or family of neuropeptides (Figure 1A). For example, consider communicating by cell phone as compared to listening to National Public Radio (NPR): a cell phone transmits a direct signal from one phone to another whereas a radio tower broadcasts a widespread message that is only detected by radios tuned to a specific channel frequency. Radios tuned to the specific channel frequency (NPR) will receive the message, while non-tuned radios will not. In this analogy, the cell phone represents fast-neurotransmitter communication and the radio represents neuropeptide communication (Figure 1B). Virtually every neuron has both ionotropic glutamate and GABAergic receptors localized to post-synaptic densities that receive specific connections from specific neurons arising from local circuits or long-range afferents. Synaptic connections between neurons by fast transmitters are akin to direct calls made via cell phones where every person has the capacity to answer or make direct calls to their neighbors or friends and family. Conversely, neuropeptidergic transmission is like radio communication where messages are broadcast globally (neuropeptide volume transmission), but since not every neuron expresses every neuropeptide receptor (e.g., not all radios are tuned in to the correct frequency) neuropeptide transmission confers specificity in the circuit. This provides cells with specific neuropeptide expression to selectively control circuit elements endowed with complementary cognate receptor.

Other principals by which neuropeptides orchestrate PFC circuit function remain unknown. For example, temporal differences in the timescale of neuropeptide action and signaling contributes to a varied timeframe of circuitry regulation found across different neuropeptides. How this temporal difference specifically impacts the effect of neuropeptide action on the circuit has not been thoroughly investigated. Furthermore, a contributor to the varied timeframe of circuitry regulation seen across neuropeptides is the presence and action of peptidases. Specifically, peptidases limit neuropeptide diffusion and prematurely terminate its action. A small number of studies indicate peptidase regulation of neuropeptide action influences neural circuit activity (Wood and Nusbaum, 2002; Trieu et al., 2022). However, little is still known and investigation of peptidase action on circuit dynamics remains a promising area of study. Moreover, although it has been established that the PFC is reliant on its intricate, layered organization for proper function, much remains unknown regarding the integration of neuropeptides and their cognate receptors into this structure (Figure 1C). Identifying layer differences in neuropeptide, receptor, peptidase localization, and effective neuropeptide concentrations across layers will be essential to increase our understanding of where neuropeptide signals originate and how they finally impact PFC circuits. Further, it is also of importance to establish how the aforementioned nuances of neuropeptide systems integrated in PFC circuits resonate with nuanced layering of neuronal arborization location of different neuropeptide and peptide receptor-containing neurons and their physiological properties. For instance, if a neuropeptide is expressed in one layer of the PFC and the receptor in another it gives the cortex layer specific intercommunication capacities. Additionally, if the branching patterns of different neuropeptide expressing neurons differ, the layers in which their arborizations reside may also differ. In turn, this leads to variability in innervation by layer specific inputs. Finally, neuropeptide action is highly intertwined with internal states and experience influenced by context, exteroceptive and interoceptive cues, motivation, arousal, and affect (Kennedy et al., 2014; Zelikowsky et al., 2018). For example, the internal state of an organism significantly regulates neuropeptide transmission through various facets. Specifically, internal state may impact neuropeptide release, peptidase activity, cognate receptor expression and function, or downstream signaling. Additionally, neuropeptides themselves may influence the maintenance or transitions between internal state or be changed as a consequence of internal state (Figure 1D). However, further investigation of the dynamic nature of internal state and neuropeptide action is required. For example, the field has yet to fully understand the dependence of PFC neuropeptide expression and function on internal state. As a last example, if a neuropeptide receptor impacts an ion channel that is preferentially utilized in specific sub-populations, then that neuropeptide system will have a cell-selective effects even if the receptor is widely expressed. Further delineating these principals is a promising avenue to further investigate how different neuropeptides differentially fit into cortical circuits.
Neuropeptide modulation of cortical circuits modifies PFC processing of sensation, perception, decision-making, cognition, and/or affective behaviors. Dysregulation of the PFC is associated with various psychiatric disorders, including depression (Hare and Duman, 2020), anxiety (Park and Moghaddam, 2017), post-traumatic stress disorder (Koenigs and Grafman, 2009), and substance use disorders (Goldstein and Volkow, 2011). Therefore, the potent regulatory effects of neuropeptides on higher-order cognition processes in the PFC could contribute to symptomology of various psychiatric disorders. To date, there is limited information on how neuropeptides govern cortical circuits and whether there is region-specific regulation of neuropeptide release (Brockway and Crowley, 2020). In turn, throughout this review, to supplement for vast gaps in knowledge of specific neuropeptide function within the PFC, we mention research in other cortical regions or culture systems to make predictions of how neuropeptides may function in the PFC. It is imperative the field further investigations of neuropeptide action within the PFC to uncover these unknowns so ultimately potential therapeutic targets to various psychiatric disorders are revealed.

NEUROPEPTIDE FAMILIES

Dynorphin
Dynorphins (Dyns) are endogenous neuropeptides that play an essential role in regulating nociceptive, cognitive, and affective information. Dyns are synthesized from the precursor prodynorphin (PDyn) (Chavkin et al., 1983), which is cleaved by the enzyme proprotein convertase 2 (PC2) (Day et al., 1998). Cleavage produces three primary forms of Dyn: Dyn A, Dyn B, and Dyn C.
and big Dyn, which consists of Dyn A and B. Each form shows a high affinity for the kappa opioid receptor (KOR) (Chavkin et al., 1982; Schwarzer, 2009). The most potent activator of KORs, Dyn A 1–17, is a 17 amino-acid peptide (James et al., 1984). Note that there are less potent forms like Dyn A1–13 and Dyn A (1–8) (Feuerstein and Faden, 1984). The first five amino acids of Dyn encode the peptide Leu-enkephalin which is essential for binding to KORs (Chavkin and Goldstein, 1981). Dyn B and big Dyn (Fischli et al., 1992) also activate KORs but possess lower KOR binding affinities than Dyn A. In addition to KOR, Dyn A1–8, a truncated form of Dyn A (Minamino et al., 1980), shows moderate affinity to both µ and δ opioid receptors (Toll et al., 1998). Dyn has also been shown to have non-opioid actions at NMDA receptors (Chen et al., 1995; Caudle and Dubner, 1998; Tang et al., 2000). Triggered by membrane depolarization, Dyn is released from DCVs localized to presynaptic or somatodendritic terminals (Molineaux and Cox, 1982; Chavkin et al., 1983; Whitnall et al., 1983; Svingos et al., 1999). Once released, Dyns mainly target KORs (Wagner et al., 1991), which are inhibitory GPCRs that activate Gi/o signaling pathways (Taussig et al., 1993). Dyn is hypothesized to mediate inter-cellular communication through volume transmission where the peptide diffuses to binding sites up to 50–100 µm from their release site as measured in the hippocampus (Drake et al., 1994; Castillo et al., 1996; Chavkin, 2000). Although not observed in the PFC, this translates as it suggests that the location of KORs and localization of peptidases that degrade Dyns are essential to understanding the spatiotemporal profile of Dyn/KOR signaling. Together, Dyn signaling through KORs and subsequent downstream effects contribute to sensory and affective information regulation.

Roughly 8% of cortical neurons express PDyn, and 3% express KORs (Smith et al., 2019). Specifically, PDyn is heavily expressed in somatostatin interneurons (Sohn et al., 2014; Smith et al., 2019). PDyn mRNA and Dyn immunoreactivity has been observed across cortical regions in several species (Khachatourian et al., 1985; Peckys and Hurd, 2001; Yakovleva et al., 2006). Still, the relative abundance of this system is over-represented in primates relative to rodents (Hurd, 1996; Merchenthaler et al., 1997; Lin et al., 2006). Thus, the role of cortical PDyn may be more relevant in humans than in rodents and suggests the Dyn/KOR system may play a unique role in humans. In turn, warranting future research. In primary sensory cortices, most PDyn-mRNA expressing neurons are GABAergic somatostatin-containing interneurons (Sohn et al., 2014; Loh et al., 2017b; Smith et al., 2019), whereas, in the PFC, most PDyn-expressing neurons are glutamatergic (Sohn et al., 2014). A recent study using PDyn-iCre mice crossed with tdTomato mice showed strong labeling restricted to superficial layers in the insular cortex (Pina et al., 2020). Rats show temporal shifts in the patterns of cortical PDyn expression at different developmental stages (Alvarez-Bolado et al., 1990) and this dynamic expression pattern is consistent with reported maturational changes in rats’ mPFC Dyn/KOR signaling patterns (Sirohi and Walker, 2015). PDyn expression may also change as a function of activity and experience. A recent study reported a transient experience-dependent increase in the percentage of somatostatin interneurons expressing PDyn (Loh et al., 2017a). This is supported by data that show regulation of human cortex PDyn expression by epigenetic changes linked to psychiatric disorders (Taqi et al., 2011; Yuferov et al., 2011; Butelman et al., 2012; Tejeda et al., 2012; Bazov et al., 2018a). These findings suggest Dyn expression can be used as a marker that represents a dynamic functional state of somatostatin (SST) interneurons that are sensitive to developmental and environmental factors underlying psychiatric disorders. However, further research is needed to validate this model.

The abundance of KOR mRNA expression in the cortex suggests that cortical sources of Dyns should affect local circuits (Meng et al., 1993; Svingos and Colago, 2002; Bazov et al., 2018b). KOR and PDyn mRNA expression patterns suggest that different cortical regions show distinct patterns of layer specificity (DePaoli et al., 1994; Peckys and Hurd, 2001; Smith et al., 2019). For example, in humans PDyn mRNA shows a different pattern of expression in the cingulate and dorsolateral PFC. Specifically, PDyn mRNA is widely spread across layers of the cingulate whereas it is tightly confined to limited layers in the dorsolateral PFC. In contrast, KOR is expressed similarly in both regions. Considering abundant expression of KOR and PDyn mRNA in the cortex, it is currently unclear how Dyn producing cells influence incoming KOR-expressing inputs or local-circuit neurons and unknown whether Dyn is released from axon terminals to act homosynaptically or heterosynaptically. It is also not known whether Dyn can be released from PFC cells from somatodendritic compartments to influence incoming inputs to Dyn neurons in a retrograde manner. Future research is necessary to address these unknowns and dissect Dyn/KOR regulation of PFC inputs. Moreover, KORs are differentially expressed in limbic afferent inputs that project preferentially to the PFC relative to primary sensory cortices (Tejeda et al., 2021). KOR mRNA shows increased expression in layer VI pyramidal neurons projecting within the telencephalon (Tasic et al., 2018; Smith et al., 2019). Ultrastructural studies show that prefrontal KOR immunoreactivity is primarily observed in presynaptic terminals with varicosities and presynaptic terminals of symmetric and asymmetric synapses, indicative of excitatory and inhibitory synapses, respectively (Svingos et al., 1999). Consistent with KOR localization on varicosities, KORs are expressed presynaptically in mesocortical dopaminergic terminals in the PFC and inhibit the release of dopamine (Tejeda et al., 2013). However, the expression of KOR in mesocortical neurons is not limited to presynaptic terminals, as KOR activation directly inhibits the activity of PFC-projecting ventral tegmental neurons (Margolis et al., 2006). KORs also regulate excitatory basolateral amygdala, but not ventral hippocampus, inputs to PFC (Tejeda et al., 2015), suggesting that the Dyn/KOR system may filter information coming into the PFC in a pathway-specific manner. KORs also potently inhibit the glutamate-driven enhancement of extracellular GABA levels, suggesting that Dyn may also regulate excitation/inhibition balance (Tejeda et al., 2013). Pathway-specific Dyn/KOR regulation of excitatory synapses and excitation/inhibition balance in different cell types has also been observed in the nucleus accumbens (Tejeda et al., 2017), which would imply that selective filtering of information flow may be a general principle of the Dyn/KOR system. Inhibitory actions...
of dynorphin on insular cortex GABA neurons have also been reported (Pina et al., 2020). Collectively, these studies suggest that Dyn/KOR signaling may regulate PFC information processing via multiple mechanisms.

Dysregulation of the Dyn/KOR system has been shown to play crucial roles in drug-seeking, appetitive, and mood disorders. KOR activation promotes aversive behavior in animal models (Mucha and Herz, 1985) and psychotomimetic, anxiogenic, aversive experiences in humans (Pfeiffer et al., 1986). Direct infusion of the KOR antagonist norBNI in either prelimbic or infralimbic cortices diminishes restraint stress-induced increases in arterial pressure and heart rate without affecting stress-induced changes in tail and body temperature (Fassini et al., 2014, 2015). This suggests that KOR signaling in the PFC increases autonomic arousal and may underlie maladaptive stress-related responses, a hallmark of anxiety disorders. Consistent with this notion, mPFC infusion of a KOR antagonist had an anxiolytic effect in an open field (Wall and Messier, 2002; Tejeda et al., 2015). Moreover, systemic or direct injection of KOR agonist in mPFC produces conditioned place aversion (CPA) (Bals-Kubik et al., 1993). Furthermore, CPA induced by systemic KOR agonist is blocked via mPFC infusion of KOR antagonist (Tejeda et al., 2013), indicating that KOR activity in the mPFC is required for KOR-mediated aversion. Other studies have identified a role for the Dyn/KOR system in the infralimbic cortex in reducing anxiety-like behavior. Intra-mPFC administration of the KOR agonist, U69,593, or the KOR antagonist, nor-BNI, reduces and increases anxiety-like behavior, respectively (Wall et al., 2001; Wall and Messier, 2002). Further insight regarding the mechanisms of the Dyn/KOR system’s regulation of autonomic, anxiety-like behavior, and aversive responses may benefit future treatments for patients with anxiety and mood disorders.

The Dyn/KOR system may also regulate cognition via regulation of mPFC circuits. A recent study found that KOR activation in the PFC decreased accuracy and responsiveness in a delayed non-match to sample working memory task (Abraham et al., 2021). These effects were recapitulated by optogenetic activation of PDyn expressing PFC neurons and blocked by local infusion of the KOR antagonist norBNI. Conversely, the Dyn/KOR system in the infralimbic cortex may promote working memory as KOR activation and inhibition enhances and decreases putative measures of working memory on the spontaneous alternation memory task (Wall and Messier, 2002; Wall et al., 2001; Wall and Messier, 2002). Collectively, these studies point to a potential role of KOR-PFC signaling in PFC-dependent working memory and this capacity may differ depending on PFC sub-regions.

What is currently unknown is how the many actions of Dyn/KOR signaling impacts the function of PFC circuits to influence behavior. Dopamine transmission and limbic inputs in the PFC are critical for cognitive processing, working memory, and decision-making (Goldman-Rakic et al., 2000; Floresco, 2013; Arnsten, 2015). The Dyn/KOR system is widespread across cortical circuits. However, unique innervation of the PFC by KOR-sensitive afferent inputs, such as the ventral tegmental area and basolateral amygdala, that convey motivationally charged information to promote executive control of behavior inherently confers the PFC Dyn/KOR system the capacity to regulate affective behavior and cognitive control. The inhibitory effect of KOR activity in dopamine and basolateral inputs to the PFC, imparts a specialized function for this system in differentially shaping PFC circuits versus primary and lower-order associative cortical circuits. Moreover, Dyn expression in PFC circuits is not restricted to GABAergic neurons, as is observed in primary sensory cortices (Sohn et al., 2014). This suggest that principal neurons may utilize this peptide to influence incoming afferents and dopaminergic inputs, providing a modular signal capable of filtering incoming information and local processing. Differential integration of the Dyn/KOR system into PFC along with unique features of the PFC may be essential contributing factors that position the Dyn/KOR system as a potent regulator of affective, defensive, arousal and executive function.

One function of the PFC Dyn/KOR system may be to regulate dendritic integration in cortical cells by virtue of the diverse actions this system has on PFC circuits. Dopamine transmission in the PFC may drive wide-spread cellular effects that culminate in increased encoding of synaptic information within dendritic compartments within specific ensembles of neurons. By directly inhibiting glutamate release via a presynaptic site of action, KOR may decrease the probability of NMDA receptor activation and subsequent recruitment of active conductances, such as voltage-gated calcium channels, to reduce responsiveness of neurons to incoming inputs (Palmer et al., 2014; Augusto and Gambino, 2019). KORs localized within dendritic processes may also influence the way KOR-positive cortical cells process information. GABAB receptors, G_{i/o}-coupled GPCRs similar to KOR, inhibit Ca^{2+} signaling through NMDA receptors (Chalifoux and Carter, 2010), which would be predicted to inhibit Ca^{2+}-regulated processes in somatodendritic compartments essential for shaping input-output transformations. Occasional co-localization of KOR and NMDA receptors in dendrites (Swingos and Colago, 2002) provides an anatomical basis for interaction between KOR and NMDA receptors similar to those with GABAB receptors. KOR activation also influences the mTOR pathway, which modifies neurite outgrowth, spinogenesis, and synaptic plasticity in cortical neurons (Liu et al., 2019), providing another mechanism by which Dyn may regulate dendritic processing in PFC KOR-containing neurons. Lastly, Dyns can positively or negatively allosterically modulate NMDA receptor activity in a KOR-independent manner (Caudle and Dubner, 1998), influencing excitatory transmission or synaptic integration. Collectively, the concerted efforts of Dyn/KOR signaling is expected to have widespread effects on PFC cortical circuit dynamics and may be important for the selection/deselection of ensembles that encode PFC-dependent behavior.

**Enkephalin**

Enkephalins (Enks) are endogenous neuropeptides and members of the opioid peptide family that play a significant role in neurotransmission and pain modulation. Enks signal through G_{i/o} opioid receptors, preferentially binding to DOR and MOR (Takahashi, 2016). Enk, DOR, and MOR expression is widely distributed throughout the central, peripheral, and autonomic
nervous systems, multiple organ systems, as well as endocrine tissues and their target organs (Hughes et al., 1975; Tang et al., 1982; Holaday, 1983; Coffield and Miletic, 1987; Duque-Diaz et al., 2017; Smith et al., 2019). There are two structurally different Enk peptides, Met-Enk and Leu-Enk which arise via proteolytic processing from the precursor proteins proenkephalin A and proenkephalin B, referred to as PDyn. Proenkephalin is enriched throughout the brain and gives rise to Met- and Leu-Enk neurons in various regions including the cerebral cortex, basal ganglia, limbic telencephalic nuclei, hypothalamus, and thalamus (Geraci et al., 2009). Proenkephalin A yields four Met-Enks, one Leu-Enk, one Met-Enk-Arg⁶-Phe⁷, and one Met-Enk-Arg⁶-Gly⁷-Leu⁸ (Dhawan et al., 1996). In contrast, PDyn yields one Leu-Enk. Leu- and Met-Enks have the highest binding affinity to DOR followed by the MOR (Schafer et al., 1991; Devi, 2001).

Enkephalin and cognate opioid receptor DOR and MOR expression in the cerebral cortex has been thoroughly characterized (Giraud et al., 1983; Taki et al., 2000; Smith et al., 2019). Single-cell RNA sequencing reveals roughly 40% of anterior lateral motor cortex (ALM) and primary visual cortex (V1Sp) cells contain the pro-enkephalin gene (PENK), 40% contain the gene encoding MOR (Oprm1), and 13% contain the gene encoding DOR (Oprd1). According to single cell sequencing, PENK is primarily expressed in VIP and parvalbumin containing GABAergic neurons, although a small subset of glutamatergic I neurons also express the gene. Similarly, although Oprm1 is mainly expressed in VIP and somatostatin GABAergic neurons, it is also expressed in a small subset of parvalbumin and layer VI glutamatergic neurons. In contrast, Oprd1 is almost exclusively expressed in somatostatin and PV cells (Smith et al., 2019). Furthermore, immunolabeling methods show neurons expressing MOR are frequently colocalized with proenkephalin, and mainly express on small, non-pyramidal neurons expressing GABA in layers II–IV (Taki et al., 2000). Immunocytochemical detection of opioid peptides in the PFC reveal widespread expression of Enk in layers II and III and V and VI of neocortex in addition to layers II and III of the olfactory cortex (McGinty et al., 1984; McGinty, 1985). Additionally, radioimmunoassays reveal the ratio of Leu-Enk to Met-Enk-Arg⁶-Gly⁷-Leu⁸ is roughly one, which corresponds with the ratio of respective precursor proteins (Giraud et al., 1983). This contrasts with other peptides where the ratio of respective precursor proteins does not correspond with the active peptide, in turn, implying the majority of PENK is converted to active Enk peptide. In summary, Enk and its cognate receptors are expressed across layers of the cortex in both glutamatergic and GABAergic neurons.

Enkephalin impinges on cortical circuitry by regulating synaptic transmission and other cortical neuromodulators. Electrophysiological findings reveal opposing roles of MOR and DOR in synaptic transmission within thalamo-cortico-striatal circuits. Specifically, MOR agonists suppress excitatory thalamic inputs to the ACC, while DOR opioid agonists disinhibit ACC pyramidal neurons by suppressing feed-forward inhibition (Birdsong et al., 2019). Therefore, DOR activation causes hyper-excitatable ACC circuits and MOR activation causes inhibition of glutamate release. This suggests Enk action on either MOR or DOR can differentially impact thalamo-cortical-striatal circuitry. Moreover, MOR modulation of cortical circuitry is subregion specific. MOR agonists acting on MORs expressed on parvalbumin-interneurons inhibit GABAergic synaptic transmission in the medial orbitofrontal cortex but not lateral orbitofrontal cortex (Lau et al., 2020). MOR antagonism does not reverse this suppression of inhibition which indicates MOR enaction of long-term depression. Ultimately, these regional differences suggest location-dependent differences in MOR coupling to downstream cAMP/PKA signaling cascades or differential expression of functional MORs. Cortical MOR also regulates dopamine action. For example, MOR activation within the PFC elevates local dopamine overflow (Tejeda et al., 2013), which provides a novel mechanism by which MORs may regulate dopamine output beyond disinhibition of dopamine neuron activity within midbrain circuits (Johnson and North, 1992; Matsui and Williams, 2011). Additionally, Enk can modulate cortical circuitry by altering the action of other neuropeptides in the system. D-Ala2-D-Leu5-Enk inhibits K⁺-stimulated release of cholecystokinin in the hypothalamus but not the cortex (Micevych et al., 1985). Contrastingly, cortical D-Ala2-D-Leu5-Enk inhibits K⁺-stimulated release of VIP in a naloxone dependent manner (Micevych et al., 1984). Together, these results indicate region-specific, elaborate modulation of cortical circuitry by Enk through MOR and DOR.

Activation of DOR and MOR and their signaling cascades by Enk has been shown to modulate information processing in cortical circuits and associated behaviors. Specifically, studies on Enk modulation of neural circuits as contributors to psychiatric disorders (e.g., addiction, anxiety, depression, and PTSD) and pain regulation are currently active areas of research. Adverse life experiences increase lifetime risk to stress-related psychopathologies, and exposure to stress downregulates endogenous Enk expression in the PFC in rats (Li et al., 2018). However, post-mortem cortical tissue from individuals suffering from substance use disorder showed upregulated PDyn and KOR mRNA, but no significant changes in expression of proenkephalin, MOR, and DOR opioid receptor mRNA was evident. This suggests KOR but not MOR signaling may underlie in part the neurocognitive dysfunctions relevant for addiction and disrupted inhibitory control (Bazov et al., 2013; Nosova et al., 2021).

Prefrontal cortex Enk and MOR signaling has been implicated in modulating reward-seeking and compulsive behaviors. MOR stimulation within the vmPFC induces feeding and hyperactivity (Mena et al., 2011, 2013; Giacomini et al., 2021). Additionally, endogenous cortical Enk transmission is both necessary and sufficient for the expression of impulsive action in a high-arousal appetitive states (Selleck et al., 2015) as well as anticipation and excessive consumption of alcohol (Morganstern et al., 2012). Opioid action in the PFC has been implicated in inhibitory-control deficits associated with addiction and binge-type eating disorders. For example, prenatal ethanol exposure led to increase in Met-Enk in the PFC which is suggested to underlie the facilitation of postnatal ethanol intake (Abate et al., 2017). Furthermore, cocaine self-administration significantly increases MOR and DOR mRNA but not proenkephalin mRNA in...
the PFC indicating changes in these targets may underlie cocaine-induced reward and habitual drug-seeking behavior (Sun et al., 2020). Cortical Enk may also regulate compulsive behaviors as models of autism spectrum disorder demonstrate a decrease in cortical endogenous Enk with an increase in repetitive behaviors (Augustine et al., 2020). Together, these studies suggest the role of Enk signaling through MOR and DOR in cortical circuit processing and associated behaviors underlying neurological disorders.

Changes in Enk cognate receptor availability also impacts cortical circuits which regulate reward and motivational processes that underlie psychiatric disorders. Specifically, positron emission tomography (PET) studies show a decrease in MOR opioid peptide binding potential in anterior cingulate for patients with PTSD (Liberzon et al., 2007). Additionally, cortical PET studies have revealed the binding potential of MOR and DOR ligands in patients with chronic neuropathic pain. Individuals experiencing central post-stroke pain had a decrease in \([^{14}C]\)-diprenorphine, a non-selective opioid receptor antagonist, in the insular and lateral prefrontal cortices and anterior cingulate (Willough et al., 2004; Maarrawi et al., 2007a). Patients with peripheral neuropathic pain had symmetrical bilateral decreases in \([^{14}C]\)-diprenorphine where patients with central post-stroke neuropathic pain primarily had contralateral asymmetrical decreases. This suggests that motor cortex stimulation (MCS) for control of neuropathic pain also decreases \([^{11}C]\)-diprenorphine binding in the anterior cingulate indicating enhanced secretion of endogenous opioids during MCS (Maarrawi et al., 2007b). However, it is unclear from these results whether decrease in opioid receptor availability is due to a loss of opioid-receptor containing neurons, available receptors, and/or increased endogenous opioid peptide release. Ultimately, given that endogenous enkephalin signaling via MOR and DOR regulates excitation-inhibition balance in a circuit specific manner, alterations in opioid receptor availability following stroke may contribute to mal-adaptive behaviors and is suggested to be one of the causes of poststroke pain. In turn, upregulation and action of MOR and DOR in the cortex indicates modulation of cortical circuits underlying pain disorders.

Given the role of Enk underlying psychiatric disorders and suggested modulation of information processing in cortical and subcortical circuits, the use of Enk as a therapeutic has been highly considered. It is important to note that therapeutics pertaining to MOR and DOR are vast, and for the purpose of this review only therapeutic treatments that aim to manipulate Enk as a peptidergic transmitter will be discussed. For a more detailed look at opioid receptor specific therapeutics please consult the following articles (Broom et al., 2002; Spetsa et al., 2013; Browne et al., 2020; Grim et al., 2020; Senese et al., 2020). To capitalize on the analgesic effects of endogenous Enks, research has been done to chemically modify Enks so they are more difficult to degrade and analgesic properties of endogenous Enks can be amplified while retaining their ligand specificity for MOR and DOR (Pert et al., 1976; Kroppotova et al., 2020). A result of these studies is the development of dual enkephalinase inhibitors (DENKIs) that enhance the analgesic effects of endogenous Enks only at sites of release, avoiding negative side effects including tolerance, respiratory depression, and constipation that derive from widespread MOR and DOR activation (Poras et al., 2014). Despite these advantages, peptidase inhibitors act on many targets and unexpected, negative impacts of their inhibition is a caveat that must be considered. Further, the coupling of Enk to the glycosylation of biopharmaceuticals improved binding to its carbohydrate receptor, pioneering a method that increases the accuracy of therapeutic peptides (Christie et al., 2014). Together, Enk is a promising therapeutic to consider for pain and psychiatric disorders.

Despite the number of studies on the neuromodulatory effects of Enk underlying analgesia and neuropsychiatric-relevant behaviors, there are still many unknowns of Enk function in cortical circuits. For example, although Enks precursor peptides proenkephalin A and Pdyn have been well established, whether there are differential effects of Enk sources arising from proenkephalin A or Pdyn has yet to investigated. Additionally, although Birdsong et al. (2019) established that MOR and DOR regulate the thalamo-cortico- striatal circuit in opposing ways and Lau et al. (2020) determined subregional differences in MOR-coupling downstream cascades, whether MOR and DOR differential regulation of the cortex works independently alongside one another or together is unknown. Furthermore, VIP neurons disinhibit the cortex by inhibiting other cortical interneurons (Millman et al., 2020). Given the colocalization of Enk and VIP expression (Smith et al., 2019; Leroy et al., 2021) and that GABAergic interneuron output at some capacity are inhibited by Enk, release by cortical VIP neurons may cooperate with VIP GABAergic transmission to disinhibit cortical circuits in a spatially- and temporally organized manner. As imbalance in excitatory and inhibitory control of PFC circuits is implicated in various neuropsychiatric disorders, it will be of importance to understand how inhibitory effects of MORs on excitatory inputs versus disinhibition by MOR/DOR may play a role in such excitation/inhibition imbalance. Ultimately, understanding the role of Enk in PFC circuits is necessary to uncover the underpinnings of various psychiatric disorders and further develop therapeutic targets and treatments.

**Corticotropin-Releasing Hormone**

Corticotropin releasing factor (CRF) plays a significant role in the integration of endocrine and behavioral responses to stress by acting on the hypothalamic-pituitary-adrenal (HPA) axis (Vale et al., 1981). However, CRF is also expressed in brain regions not associated with the HPA axis such as the cortex. Originating from a 196 amino acid prepropeptide, CRF is synthesized by prohormone convertases at dibasic amino acids (lysine or arginine) to produce a 41-amino acid mature peptide (Hook et al., 2008). CRF is a member of the CRF system comprised of CRF and three additional neuropeptides: Urocortin I (UCNI), Urocortin II (UCNII), and Urocortin III (UCNIII). As there is little known regarding Urocortins in cortical circuits, this review will only cover CRF within the CRF system. CRF has two cognate GPCR receptors, CRF type-1 (CRF1) and CRF type-2 (CRF2) (Dedic et al., 2018), which are fairly similar and share 70% amino acid identity. Despite this similarity, CRF receptors differ in their N-terminal extracellular domain (40% identity).
Corticotropin releasing factor peptides act through CRF receptors with varying affinity (Dedic et al., 2018). Specifically, CRF has a higher affinity for the CRF1 than CRF2 receptor. Although CRF receptors couple primarily to Gs proteins (Millan et al., 1987), they can bind and activate other G proteins as well (Grammatopoulos and Chrousos, 2002; Hillhouse and Grammatopoulos, 2006). This suggests CRF receptors may couple to various signaling pathways. CRF1 activation by CRF or UCN1 and CRF2 receptor activation by UCN1, UCNII, or UCNIII can activate ERK1/2 in CHO cells (Brar et al., 2004). Moreover, CRF selectively activates ERK1/2 in different regions of the brain via CRF1 in vivo (Refojo et al., 2005). In PFC synaptosomes, UCNIII induces activation of ERK1/2 (Yarur et al., 2020a). Together, these studies indicate CRF receptor signaling pathways are determined by specific G-protein coupling and availability of cellular signaling components in CRF-containing cells.

Corticotropin releasing factor type-1 and CRF2 are expressed in the olfactory bulb, bed nucleus of the stria terminals, lateral septum, paraventricular nucleus of the thalamus, dorsal raphe nucleus, and mPFC where expression of CRF1 is greater than CRF2 (Van Pett et al., 2000). In the mPFC, CRF is expressed in neurons across all layers (Yan et al., 1998). CRF is expressed in inhibitory interneurons, primarily in parvalbumin cells and rarely in calbindin or calretinin-expressing cells (Yan et al., 1998). UCNs expression in the cortex is present in sparse fibers in deeper layers (Bittencourt et al., 1999). CRF1 receptor is widely expressed in pyramidal cells of the mPFC (Uribe-Marino et al., 2016). There is also evidence of CRF1 expression in inhibitory interneurons as the receptor is often co-expressed with other peptides found in various interneuron populations like somatostatin, VIP, and cholecystokinin (Gallopin et al., 2006). To date, there is no conclusive evidence showing the expression of CRF2 receptor within mPFC circuits (Van Pett et al., 2000). However, CRF2 receptor expression on basolateral amygdala inputs to the mPFC have been described (Yarur et al., 2020b). Collectively, these studies suggest that the CRF system is integrated into PFC circuitry and may regulate circuit dynamics.

Studies show CRF modulates PFC synaptic transmission. Iontophoretic application of CRF enhances the activity of neurons in the cortex of Sprague–Dawley rats (Eberly et al., 1983). In addition, CRF bath application increases sEPSC frequency in layer V pyramidal cells from rat PFC slices, an effect that can blocked a by a CRF1 receptor antagonist (Liu et al., 2015). These results suggest that CRF enhances excitatory drive onto PFC principal neurons. Interestingly, lesions of the basolateral amygdala reduced CRF enhancement of sEPSC frequency of ipsilateral layer V pyramidal cells in PFC (Liu et al., 2015), suggesting that basolateral amygdala synapses are a site of action for CRF. Similar results were found in layers II/III and V of adult male C57BL/6J mice (Hwa et al., 2019), where the increases in sEPSC frequency induced by fox odor were ablated by the administration of a systemic CRF1 receptor antagonist.

Pretreatment with CP154526, a CRF1 antagonist, suppresses defensive burying and reduces enhanced synaptic transmission elicited by predator exposure. The increase in sEPSC by fox odor exposure occludes the increase of sEPSC induced by CRF bath application, implying that predator odor-related behaviors engages the CRF system in the PFC. Collectively, these studies are consistent with a facilitatory role of CRF on excitatory transmission in the PFC. CRF may also interact with the serotonin system within PFC circuitry. PFC 5-HT signaling has been implicated in anxiety and stress behaviors. 5-HT increases the amplitude and frequency of sIPSCs in the rat PFC (Tan et al., 2004). Co-application of CRF and 5-HT prolong the effects of 5-HT on sIPSC, an effect blocked by astressin, a CRF1 antagonist. Collectively, these studies suggest that CRF regulates synaptic transmission in the mPFC and may be recruited by stressors.

Prior studies reveal dynamic changes in cortical CRF systems in response to stress. Acute restraint stress increases CRF and CRF1 mRNA in the PFC of Sprague–Dawley rats (Meng et al., 2011). On the other hand, chronic social defeat stress decreased CRF mRNA and increased CRF1 mRNA in PFC of Wistar rats (Boutros et al., 2016). In adult males, chronic social defeat stress modified mRNA for CRF receptors only in susceptible animals, but not resilient mice (Guo et al., 2020). In comparison to control and resilient mice susceptible mice, susceptible mice show increased CRF1 mRNA and decreased CRF2 receptor mRNA expression. These results suggest condition and duration of the stressor can differentially regulate CRF to contribute to stress-coping deficits with chronic stressors.

Corticotropin releasing factor modulation of PFC function and behavior is a rising area of study. Infusion of CRF in the PFC impairs working memory while an infusion of NBI 35965, a CRF1 antagonist, improves working memory (Hupalo and Berridge, 2016). Moreover, PFC CRF neuron activation inhibits working memory, an effect blocked by intra-mPFC CRF1 antagonism (Hupalo et al., 2019). Interestingly, mPFC CRF signaling decreased PFC, and to a lesser extent striatal, neuron task-related encoding. However, intra-mPFC administration of CRF does not modify sustained attention (Hupalo and Berridge, 2016), suggesting that CRF signaling in the PFC may differentially regulate different aspects of PFC-dependent cognition. Interestingly, chemogenetic activation of PFC CRF-expressing neurons impairs working memory, an effect blocked by systemic, but not intra-mPFC, administration of a CRF1 antagonist. The authors concluded that effects of CRF neuron activation is due to release of CRF in PFC terminal regions. This work establishes a role for PFC CRF systems in regulating cognitive function. Further, CRF-containing neurons in the PFC regulate motivated behavior under stress. Specifically, a subset of PFC CRF-containing interneurons is recruited in tail suspension test and ablation or inhibition of these neurons increase immobility time in mice (Chen P. et al., 2020). Interestingly, activation of CRF neurons promotes resilience. These results suggest CRF neurons may become engaged to promote adaptive behaviors to overcome stress rather than driving mal-adaptive behavior. In a mouse model of stress-induced depression, the ablation or antagonism of CRF1 receptors abolishes behavioral despair (Dedic et al., 2018; Deussing and Chen, 2018). Thus, the...
PFC CRF may control adaptive and/or mal-adaptive behaviors depending on the severity and/or duration of the stressor. Microinjection of CRF into the PFC increases anxiety-like behavior in the elevated plus-maze (EPM) in both acute and chronically stressed rats (Jafari and Bhatnagar, 2007). CRF injection in the rat frontal cortex induces anxiogenic actions, but at high doses produces an anxiolytic-like effect (Zieba et al., 2008). Interestingly, the anxiolytic action of may be mediated by engagement of alpha-adrenergic signaling (Smialowska et al., 2021). CRF1 receptor in the PFC has been implicated in the emotional adaptation to stress (Uribe-Marino et al., 2016). Consistent with the CRF-5-HT interactions mentioned above, CRF/CRF1 transmission regulates anxiety-related behaviors through 5-HT2R signaling in the PFC (Magalhaes et al., 2010), indicating that the CRF system interacts in the PFC with other neurotransmitters such as serotonin and norepinephrine to regulate anxiety-like behaviors. Collectively, these studies suggest that PFC CRF systems regulate PFC-dependent behaviors, including anxiety-like behavior and cognition.

There is a wide array of evidence that suggests that CRF is a viable target for the treatment of psychiatric disorders. Preclinical and postmortem studies show elevated CRF concentrations in patients diagnosed with major depressive disorder (Nemeroff et al., 1984; Raadsheer et al., 1995; Deussing and Chen, 2018). Furthermore, there is compelling evidence that the progression from recreational to compulsive drug use is driven by a shift in emotional and motivational homeostasis to an allostatic setpoint, resulting in a state of decreased reward function and increased stress responsivity. It is hypothesized that the CRF system plays a significant role in the negative emotional state and habitual drug-seeking in individuals with severe addiction (Silberman et al., 2009; Koob, 2010; Zorrilla et al., 2014). Based on the hypothesis that CRF system dysregulation contributes to negative affect, various clinical trials using CRF1 receptor antagonists have been completed, with conflicting results (Squierling and Zorrilla, 2017). A CRF1 receptor antagonist, NBI 30775/R121919, reduced depression and anxiety scores using patient and clinician ratings without achieving significant differences compared to placebo (Dunlop et al., 2000). Further, a clinical trial in major depressive disorder patients reports that a non-peptidic CRF1 receptor antagonist, NBI 30775/R121919, reduced depression and anxiety scores using patient and clinician ratings without achieving significant differences compared to placebo (Dunlop et al., 2000). In contrast, CRF1 receptor antagonist CP-316,311 did not reduce depression or anxiety symptoms compared to placebo (Dunlop et al., 2014). These studies suggest that PFC CRF systems regulate PFC-dependent behaviors, including anxiety-like behavior and cognition.

Although extensive research has been done on the CRF system in the frontal cortex, much remains unknown about its architecture and function in cortical circuits. It is unclear how CRF modulates the activity of the cortical circuitry via regulation of local circuit excitatory and inhibitory neurons and afferent inputs to the cortex. Despite extensive research on the role of the CRF system in regulating stress-related and anxiety-like behavior, little is known about the role of this system in regulating reward processing beyond the context of cognitive tasks. Given that PFC CRF neurons regulate encoding of working memory (Hupalo et al., 2019), it will be of interest to understand how CRF system shapes PFC activity to acute and chronic stressors and during reward processing. It is also unknown how CRF binding protein (CRFBP) influences the CRF system in the PFC. CRFBP was first postulated as a sequester of CRF, effectively reducing CRF concentration and receptor activity (Cortright et al., 1995). Further studies have revealed other actions of CRFBP. Specifically, CRFBP has been shown to have a facilitatory role of CRF-induced potentiation of NMDAR-mediated synaptic transmission in the ventral tegmental area (Ungless et al., 2003), function independently of the CRF receptor (Chan et al., 2000), and act as an escort protein to traffic CRF2a to the cell surface (Slater et al., 2016). CRFBP is expressed in GABAergic cells in the PFC (Ketchesin et al., 2017), whereas CRF and CRF1 receptor expression is primarily observed in glutamatergic cells. This raises the question of how CRF–CRFBP interactions may modulate activity of PFC circuitry during motivationally charged behaviors. Lastly, it is unclear whether urocortins influence prefrontal cortical circuits and behavior given that they differentially activate CRF1 and CRF2 and these receptors may differ in their anatomical location within the cortex.

**Cholecystokinin**

Cholecystokinin (CCK) is a neuropeptide and gut hormone that belongs to the gastrin family and has various regulatory functions in the brain and gut. In the nervous system, CCK regulates learning and memory, nociception, homeostatic sensation, affective behavior, and drug-seeking behavior (Reisi et al., 2015). CCK peptides evoke downstream signaling pathways via CCK-A and CCK-B receptors, which signal through Gαq protein to activate phospholipase Cβ and increase intracellular Ca2+ levels (Johnsen, 1998; Williams et al., 2002).

Radio-immune and *in situ* hybridization studies reveal CCK expression is abundant in the cerebral cortex (Beinfeld et al., 1981; Savasta et al., 1988; Ingram et al., 1989; You et al., 1993) and mainly expressed in cortical interneurons (Vanderhaegen et al., 1981; McDonald, 1982; Hendry et al., 1983; Morino et al., 1994; Gallopin et al., 2006). Single cell reverse transcription polymerase chain reaction experiments indicate CCK mRNA is expressed in approximately 30–40% of GABAergic interneurons in the cortex (Gallopin et al., 2006). Moreover, CCK and CCK mRNA is expressed in both glutamatergic and GABAergic neurons (Radu et al., 2001). CCK-expressing interneurons predominantly display fast-spiking properties, with a smaller subset displaying non-fast-spiking properties (Nguyen et al., 2020). CCK-positive interneuron synaptic transmission is
stronger onto intra-telencephalic (contralateral cortex-projecting PFC neurons) than PAG-projecting pyramidal cells (Liu et al., 2020), indicating that CCK-positive interneurons in the PFC impose inhibitory control of pyramidal output neurons based on output. CCK-positive neurons are also projection neurons. Intersectional genetic approaches reveal CCK-GABAergic cells are more predominant in higher order associative cortices, including both ventral and dorsal aspects of the mPFC, relative to PV-GABAergic cells (Whissell et al., 2015). This suggests there is regional specialization of soma-targeting neurons that utilized CCK as a neuropeptide.

Despite advancements in understanding how CCK-expressing cells are embedded in cortical circuits and use fast inhibitory and excitatory amino acid neurotransmitters to regulate circuit function, there is less known about how these cells use CCK as a peptide transmitter. CCK-immunoreactivity is observed in inhibitory symmetric synapses in the cortex of rodents and non-human primates, suggesting release of CCK along with GABA within the cortex (Hendry et al., 1983). Furthermore, studies delineate that CCK-B receptors are extensively expressed in neocortical pyramidal neurons, and activation of these receptors by their endogenous agonist (CCK) depolarizes and evokes spiking of pyramidal cells (Gallopin et al., 2006). Consistent with this finding, CCK action through CCK-B receptors produce a long-lasting excitation of layer VI neocortical neurons via inhibition of a K+ leak current (Chung et al., 2009). Since layer VI pyramidal neurons densely innervate thalamic nuclei, these results imply that CCK modulates corticothalamic circuitry. Similar CCK-induced increases in pyramidal cell excitability have also been observed in hippocampal circuits (Dodd and Kelly, 1981; Boden and Hill, 1988). The capacity for CCK to regulate excitability of cells in cortical circuitry, may modify higher level processing and synaptic plasticity. For example, endogenous CCK is released in auditory cortex in response to high frequency stimulation and is necessary for long-term potentiation of excitatory transmission (Chen et al., 2019).

Interestingly, optogenetic inhibition of CCK positive interneurons in the PFC, impaired working memory retrieval in mice (Nguyen et al., 2020). However, it is unclear how the neuropeptide in this cell population may contribute to working memory. Notably, CCK expression and release may be modified by behavioral experiences. For instance, extracellular CCK levels as assessed by micro-dialysis are increased in the frontal cortex of rats in response to restraint stress, the anxiogenic drug yohimbine, and ether (Nevo et al., 1996). Further, rats exposed to a foot-shock stress paradigm show increased CCK-immunoreactivity in the PFC (Siegel et al., 1984). Arousal induced by saline injections is associated with a delayed increase in tissue CCK levels, an effect that is blocked by ketamine pretreatment. A CCK-releasing circuit from the entorhinal cortex to the auditory cortex is critical for associative aversive learning and experience-dependent plasticity (Chen et al., 2019), highlighting the importance of CCK transmission in shaping information processing within cortical circuits and associated behaviors. Additionally, activation of the CCK receptor B by endogenous CCK increases the time mice spend in the open arms of an Elevated Plus Maze behavioral paradigm (Ballaz et al., 2020). This study suggests that CCK and CCK-B receptor drive anxiolytic effects in mice, in addition to aversive learning. Collectively, these studies suggest that CCK, as a peptide transmitter in cortical circuits may be recruited during motivationally charged behaviors to impact circuit function and appropriate PFC-dependent behavior.

Despite the extensive research on CCK and the downstream effects of CCK-A and CCK-B receptor signaling, much remains unknown. It is unclear what the role of CCK originating from GABAergic interneurons versus excitatory neurons is in shaping information processing and behavior. It was previously established that CCK neurons in the amygdala play an important role in modulating fear and anxiety like behaviors, yet the mechanisms of action of CCK in frontal cortical circuits remains unclear (Truitt et al., 2009; Brown et al., 2014; Schmidt et al., 2014). Additionally, CCK has a high degree of homology to gastrin, which shares a common c-terminal sequence (Johnsen, 1998; Baldwin et al., 2010). Like CCK, gastrin signals via CCK-A and CCK-B receptors. In the nervous system, including the cortex, gastrin binds to CCK-B with high affinity (Johnsen, 1998). Immunohistochemistry studies note CCK- and gastrin-positive cells throughout the cortex (Vanderhaeghen et al., 1981), however, it is unclear if gastrin produces analogous effects to CCK, given its high affinity for the CCK-B receptor. Advancements in basic science will be pivotal for determining whether off-label use of CCK ligands in the pipeline for other psychiatric disorders, but also gives rise to other areas of research.

Somatostatin

The neuropeptide SST was first isolated from hypothalamus and identified as somatotropin-release inhibiting factor (SRIF) (Kruleich et al., 1968; Brazeau et al., 1973). There are two active forms of SST derived from the pre-prosomatostatin peptide but differ in amino acid length: SST-14 and SST-28 (Brazeau et al., 1973; Esch et al., 1980; Pradayrol et al., 1980; Schally et al., 1980). Both SST peptides are expressed in the CNS, however the expression and cellular distribution of these two forms varies between cortical and subcortical brain regions (Epelbaum, 1986). SST is stored in large DCVs and released in a calcium-dependent manner (Tapia-Arancibia et al., 1989; Bonanno et al., 1991). SST release from cortical neurons driven by excitatory transmission (Song et al., 2021) and is potentiated by stimulation of other neuropeptides and neuromodulators, such as neurotensin, VIP, and dopamine (Robbins and Landon, 1985; Thal et al., 1986). SST release in cortical slices has also been documented in response to optogenetic stimulation (Dao et al., 2019). SST release is under the inhibitory control of GABAB receptors, suggesting that SST release is gated by inhibitory neurons as well. Thus, SST release is under bi-directional control in cortical circuits, and is recruited in response to activity and neuromodulation.

Upon release from DCVs, SST binds to its cognate SST receptor (SSTR). Five SSTRs have been cloned and characterized: SSTR1–SSTR5. All SSTRs are G coupled GPCRs and bind both
SST14 and SST-28 with high affinity. SSTR-1–4 exhibit higher binding affinity for SST-14 than SST-28, while SSTR-5 has greater selectivity for SST-28 (Reisine and Bell, 1995; Barnett, 2003). Expression of all five SSTRs has been demonstrated in the cortex, with SSTR1 and SSTR2 as the two most prominent SSTRs in the human and rat cerebral cortices (Dournaux et al., 1996; Bologna and Leroux, 2000). Immunohistochemical analysis of SSTR expression in the somatosensory cortex suggest that SSTRs are differentially localized to different layers (Lukomska et al., 2020). SST activation of SSTRs generally suppresses the release of hormone or neurotransmitter from target neurons by activating a G-protein signaling pathway that inhibits adenylyl cyclase and calcium channels (Martel et al., 2012). Cortistatin (CST), a neuropeptide naturally expressed in the cortex, is another endogenous ligand that can bind to SSTR. CST has the same amino acid sequence at the receptor binding site as SST and studies show that CST can activate all subtypes of SSTRs with nanomolar affinity to induce similar signaling consequences as SST (de Lecea, 2008; Song et al., 2021). Together, SST and CST act through SSTRs to enact G-protein signaling cascades that regulate neural function.

Somatostatin-expression has been identified in neurons throughout the mammalian brain. In the cerebral cortex, SST is expressed predominantly in a subgroup of GABAergic interneurons. SST-positive GABAergic neurons represent approximately 30% of the total cortical interneuron populations (Rudy et al., 2011; Urban-Ciecko and Barth, 2016). SST interneurons provide dendritic inhibition onto pyramidal neurons to regulate integration of excitatory inputs (Liguiz-Lecznar et al., 2016). Further studies reveal SST neurons are heterogenous and show diverse properties in firing pattern, arborization, connectivity, and transcriptome profiles (Fishell and Rudy, 2011; Tasic et al., 2018; Naka et al., 2019). Using an unbiased, large-scale profiling method, Jiang et al. (2015) analyzed that cortical SST neurons consist of three subpopulations: low-threshold or irregular-spiking Martinotti neurons, fast spiking basket cells, and bitalured cells. Thus, multiple types of cells in the cortex have the potential capacity to release SST peptides in addition to GABA.

Electrophysiological studies have demonstrated that SST application results in heterogeneous effects on excitability cortical neurons, with excitation being the most prominent (Olpe et al., 1980; Delfs and Richter, 1983). Increases in activity in response to SST have also been reported in the hippocampus (Mueller et al., 1986). IPSPs are also inhibited by SST application (Leresche et al., 2000). Recent work has started to dissect how SST may facilitate spiking. SST decreases excitatory synaptic transmission onto PV-expressing interneurons, but not pyramidal neurons, via a presynaptic mechanism (Song et al., 2020). Importantly, this effect was recapitulated by endogenous SST release evoked by optogenetic stimulation of SST neurons, providing a potential mechanism for principal neuron disinhibition. SST-immunoreactivity is observed near GABA release in presynaptic terminals that appose excitatory terminals (Kecskés et al., 2020; Song et al., 2020). This anatomical framework is consistent with a role of SST in regulating excitatory synaptic transmission via a presynaptic site of action. SST may also have direct post-synaptic actions on cortical pyramidal neurons. SST-14 and SST-28 enhance and decrease delayed-rectifier potassium currents in cultured cortical neurons, respectively (Wang et al., 1989). SST signaling via SSTR4 induces hyperpolarization of principal neurons has also been observed in the medial entorhinal cortex (Kecskés et al., 2020), an effect that is more robust in layer III/V than layer II neurons. This is consistent with a role of SSTR4 in retinal ganglion cells in inhibiting L-type Ca2+ channels, which enhance intrinsic excitability (Farrell et al., 2014). SST also hyperpolarizes principal neurons in the CA1 of the hippocampus (Mueller et al., 1986). Collectively, these data provide circuit-based mechanisms wherein SST release may regulate information processing in cortical circuits.

Since SST neuropeptide transmission has the potential to influence synaptic transmission and intrinsic excitability in cortical circuits, it is of no surprise that numerous studies have demonstrated that cortical SST interneurons play a critical role in sensory processing, motor control, cognition, and emotion. However, evidence linking SST peptides and their receptor system directly with these cortical functions is limited. Intraventricular (ICV) infusion of SST peptide in rats induced anxiolytic- and antidepressant-like effects in the EPM and forced swim test, respectively (Engin et al., 2008). The anxiolytic effect was recapitulated following ICV infusions of a selective SSTR2 receptor agonist, whereas the antidepressant-like effect was mimicked following infusions of either SSTR2 or SSTR3 agonists (Engin and Treit, 2009). Increasing evidence have shown that heightened brain SST level counteracts stress-induced ACTH, catecholamine, and CRF release, suggesting that SST suppresses stress-induced responses (Brown et al., 1984; Stengel and Tache, 2017). Similar roles of SST neurons in mediating working memory, fear conditioning, and enhancing circuit performance have also been described (Kim et al., 2016; Abbas et al., 2018), yet the role of the SST neuropeptide in this process is unclear. In the olfactory system, infusion of a SSTR2 agonist into mouse main olfactory bulb (MOB) increases gamma oscillation, synaptic transmission, and enhances odor discrimination performances (Lepousez et al., 2010), suggesting that enhancement of circuit performance may be a feature of SST signaling. Recently, Song et al. (2020) found that SST application in the primary visual cortex (V1) improves visual discrimination in freely moving mice and enhances orientation selectivity of V1 neurons. Further, they demonstrated that SST improves visual perception by enhancing visual gain of V1 neurons via a reduction in excitatory synaptic transmission to PV fast-spiking interneurons but not to regular-spiking neurons (Song et al., 2020). Thus, SST peptide in cortical circuits regulates information processing to shape behaviors subserved by the cortex.

Somatostatin expression in the cortex is impacted in a plethora of neuropsychiatric disorders (Crowley and Kash, 2015; Song et al., 2021). A decrease in SST expression in the cortex is observed in neurodegenerative and psychiatric disorders such as Alzheimer’s disease (Davies et al., 1980; Kumar, 2005), Parkinson’s disease (Epelbaum, 1986; Iwasawa et al., 2019), Huntington’s disease (Rajput et al., 2011), major depressive disorder (Rubinow et al., 1985; Tripp et al., 2011; Lin and Sibille, 2015), bipolar disorder (Fung et al., 2014;
Pantazopoulos et al., 2017), and schizophrenia (Reinikainen et al., 1996; Hoftman et al., 2015). Interestingly, SST neuron activity is necessary for the antidepressant effects of scopolamine (Wohleb et al., 2016), suggesting that decreased activity of SST neurons potentially drives depressive-like behavior. Given preclinical evidence that the brain SST system has profound anxiolytic and anti-depression effects (Crowley and Kash, 2015; Song et al., 2021), this system has therapeutic potential for treating neuropsychiatric disorders. Several synthetic SST analogs have been developed for clinical treatment of endocrine diseases, digestive diseases, and carcinogenic tumor (Gomes-Porras et al., 2020). However, no drugs targeting the SST system are approved or under investigation in clinical trials for the treatment of neurodegenerative and psychiatric disorders, mainly because current SST analogs cannot penetrate the blood–brain barrier (Lamberts et al., 1996). New drug packaging and delivery approaches, as well as gene therapy techniques, will facilitate the development of CNS-targeted SST drugs and genetic treatments.

Despite extensive research on the action of and therapeutic potential of SST and SST receptors, much remains unknown about the role of this system in shaping cortical circuits. Recently, activity-dependent cortical SST release via optogenetic stimulation was used providing a potential platform to probe the influence of circuit manipulations and/or behavior on SST release (Dao et al., 2019). Cortical SST neurons are diverse in terms of their molecular profiles, anatomical features, and electrophysiological properties. Considering the distinct firing patterns of SST neuron subpopulations, it is imperative to understand how SST release is fine-tuned by different forms of neuronal activity of diverse types of SST neurons. Furthermore, whether SST acts on different targets and cell compartments differently due to its layer-specific arborization is an unknown. Additionally, other neuron peptides, such as NPY and Dyn, are co-expressed with SST in subpopulations of interneurons (Sohn et al., 2014; Smith et al., 2019) but it is unknown whether SST can be co-released with other peptides from the same site, and how different neuropeptides released from the same neuron shapes cortical signposting processing. Further, CST is also predominantly expressed in cortical GABAergic neurons and often co-expressed with SST (Smith et al., 2019). Additional investigations are needed to understand whether CST and SST peptides that target the same receptors work synergistically, competitively, and/or in parallel in cortex. In summary, the cortical SST system influences cortical information processing. Activation of this system induces anxiolytic and anti-depression effects, and deficits in this system are observed in neurodegenerative and neuropsychiatric disorders. Understanding the nuanced mechanisms by which the cortical SST system shapes cortical information processing and control of behavior will significantly advance the development of new therapeutic treatments for neurological disorders.

**Neuropeptide Y**

First isolated in 1982 from the porcine hypothalamus, NPY is one of the most widely expressed neuropeptides in the central and peripheral nervous systems (Tatemoto, 1982). NPY consists of 36-amino acid residues and belongs to the family of pancreatic hormone polypeptides (PP). NPY is derived from its 97-amino-acid precursor peptide, pre-pro NPY, into a mature 36 amino-acid NPY1-36, which is cleaved by the enzyme dipeptidyl peptidase 4 to produce NPY3-36 (Aizawa-Abe et al., 2000; Robich et al., 2010; Dvorakova et al., 2014). NPY has widespread cardiovascular, immune, metabolic, and reproductive functions in the peripheral nervous system and regulates neural function underlying feeding, stress-, and addiction-related behaviors (Heilig, 2004; Hirsch and Zukowska, 2012). Expression of NPY is well conserved across species, including the rat, mouse, and humans across multiple brain regions, such as the hypothalamus, cortical areas, the septum, hippocampus, olfactory bulb, and striatum (Dumont et al., 1992). The widespread effects of NPY are mediated by a family of rhodopsin-like GPCRs: Y1, Y2, Y4, Y5, and Y6. The Y6 receptor subtype is functional in the mouse and rabbit but not in humans and other primates while being absent in the rat (Larhammer and Salaneck, 2004). Notably, there are mixed reports regarding the existence of a Y3 receptor subtype, given that attempts at cloning this receptor have not been successful (Gehlert, 1998; Lee and Miller, 1998; Pedragosa Badia et al., 2013). NPY receptors are predominantly located post-synaptically except for the Y2 receptor, which is pre-synaptically located (Decressac and Barker, 2012). Activating NPY receptors may initiate multiple signaling cascades associated with Gi/o proteins (McQuiston and Colmers, 1996; Sah and Geraci, 2013). Altogether, these studies highlight the need for studying the neuromodulatory role of NPY in regulating cortical physiology and behavior.

Neuropeptide Y is found in layers I, II, V, and VI of the human cortex (Adrian et al., 1983; Chan-Palay et al., 1985; Van Reeth et al., 1987) and highly colocalized with GABA and SST (Sawchenko et al., 1985; Aoki and Pickel, 1989). Although expressed by both pyramidal cells and interneurons, NPY is predominately found in interneurons (Dawbarn et al., 1984; Hendry et al., 1984; Karagiannis et al., 2009) and can be categorized into three main classes: neoglia form-like neurons, Martinotti-like, and parvalbumin-positive basket cells (Karagiannis et al., 2009). Together, NPY and cognate receptors modulate synaptic excitability and function in cortical areas (Dumont et al., 1992). Specifically, NPY has been shown to reduce the EPSCs and decrease AMPA receptor-mediated glutamatergic neurotransmission onto neocortical pyramidal neurons (McQuiston and Colmers, 1996; Bacci et al., 2002), an effect that has also been observed in other brain regions like the hippocampus (McQuiston and Colmers, 1996; Qian et al., 1997) but not the amygdala (Molosh et al., 2013). Furthermore, NPY also regulates GABAergic neurotransmission onto pyramidal neurons in the neocortex (Bacci et al., 2002), suprachiasmatic nucleus (Chen and Van Den Pol, 1996), thalamus (Sun et al., 2001), but not the hippocampus (Klapstein and Colmers, 1993). Specifically, Bacci et al. (2002) found that NPY produces delayed and long-lasting decreases in EPSCs and increases in IPSCs in pyramidal neocortical neurons, an effect likely due to Ca2+-dependent enhancement of presynaptic GABA release. Furthermore, it was found that NPY also decreased IPSCs in GABAergic interneurons, suggesting NPY may inhibit pyramidal neurons by disinhibition of GABAergic interneurons. Consistent
with the observations that NPY decreases neuronal excitability, functionally, NPY is known to have antiepileptic effects (for a review, see Vezzani and Sperk, 2004) and to provide neurons with protection against cytotoxicity by decreasing microglial reactivity, the release of microglial bioactive factors, NMDA currents and excessive Ca\(^{2+}\) entry into neurons (Li et al., 2014). Altogether, these studies suggest that NPY decreases the excitability of cortical circuits.

Neuropeptide Y signaling in the frontal cortex has been linked to affect-related disorders, highlighting the importance of characterizing the neuromodulatory role of NPY for psychiatry. On one hand, reduced NPY activity in cortical circuits has been associated with a plethora psychiatric disorders including anxiety, depression, and PTSD in both preclinical and clinical studies (Zhou et al., 2008; Mickey et al., 2011; Cohen et al., 2012; Melas et al., 2012, 2013; Sah and Geracioti, 2013). Previous work has found low levels of NPY expression in cortical brain regions of humans with a history of depression and death by suicide (Widdowson et al., 1992). Consistent with clinical work, preclinical studies report decreased cortical NPY, and Y1 receptor gene and protein levels expression in animal models of depression (Husum et al., 2001; Jimenez-Vasquez et al., 2007). Indeed, NPY and Y1 receptor agonists have been shown to decrease anxiety-like behavior, fear-suppressed food reinforcement, contextual fear, and social avoidance in rodents (Heilig et al., 1989; Sajdyk et al., 1999; Comeras et al., 2021). However, other reports have shown that activation of the NPY system in the infralimbic cortex impairs the retrieval of extinction in rats (Vollmer et al., 2012). Therefore, NPY-mediated inhibition of cortical circuits may also underlie deficits in fear extinction. Consistent with these findings, a clinical report found a link between impaired recall of extinction memory and reduced vmPFC activation in patients with PTSD (Milad et al., 2009). Together, these studies suggest that NPY modulation of cortical function underlies the etiology affect-related disorders.

Despite a breadth of studies demonstrating that NPY influences alcohol use disorder a few have suggested a link between cortical NPY signaling and alcohol use disorder (Mayfield et al., 2002). Alcohol preferring rats have low levels of NPY in cortical structures (Ehlers et al., 1998) and alcohol withdrawal produces significant reductions in NPY protein in several brain regions, including layers IV and V of the frontal cortex in the rat brain (Roy and Pandey, 2002). Additionally, rats fed an ethanol diet show reduction in NPY-immunoreactivity in the cortex (Bison and Crews, 2003). Previous work suggests that the ability of NPY to decrease alcohol consumption may be in part due to its ability to relieve alcohol withdrawal-induced anxiety (Thorsell and Mathé, 2017). Together, these results suggest that NPY-mediated inhibition of cortical circuits may play a role in the symptomatology observed in mood-and alcohol-related disorders and highlight the potential of NPY-based therapeutics for mental illnesses. Furthermore, the clinical relevance of the NPY system is evident in the clinical interest of NPY-based pharmacotherapies for treating numerous conditions. For example, a recent study suggests that NPY may be an effective treatment for anxiety in patients who have PTSD (Sayed et al., 2018) and intranasally administered NPY may produce rapid antidepressant effects (Mathé et al., 2020). These studies highlight a rich potential in the neuromodulatory role of NPY for the development of pharmacotherapies for treating psychiatric conditions such as anxiety disorders and depression.

In summary, extensive work demonstrates that NPY is a highly conserved neuropeptide involved in disease pathophysiology in the brain. While previous work demonstrates the potential of NPY-based pharmacotherapies for treating psychiatric illnesses, further work is needed to understand the functional effects of NPY signaling and its implications for brain diseases. For example, it is presently known that NPY is expressed within diverse interneuron populations that subserve distinct cortical and behavioral functions (Karagiannis et al., 2009; Smith et al., 2019). However, the role of NPY release from these different interneuron populations on cortical information processing and behavior is unknown. Moreover, NPY is also expressed in glutamatergic neurons of the PFC and it is unclear whether these cell populations release this peptide locally or in distal regions to influence behavior. Lastly, it is unclear whether NPY originating from interneurons and excitatory neurons may cooperate to more efficiently activate all pools of NPY receptor or whether NPY originating from interneurons would bind to sets of NPY receptors that are not accessible to NPY released from excitatory neurons. Understanding how NPY shapes PFC activity will help understand the role of NPY the NPY system in driving behavior under normal and pathological conditions.

**Vasoactive Intestinal Peptide**

Vasoactive intestinal peptide is a peptide and member of the glucagon/secretin superfamily that signals through VIP receptors 1 and 2 (VPACR 1 and 2). VIP receptors are GPCRs that signal via the G\(_i\) signaling pathway. The VIP precursor gene, pre-proVIP, encodes for VIP as well as the peptide histamine isoleucine (PHI) and its human form, peptide histidine methionine (PHM), that both have a lower binding affinity for both VPACRs (Rangon et al., 2005; Igarashi et al., 2011). Different concentrations of VIP may confer differential activation of VPACR 1 and 2. For instance, lower concentrations of VIP (approximately 1 nM) activate VPACR 1/2 and pituitary adenylate cyclase receptor (PAC1-R) in the hippocampus leading to increased NMDA excitatory postsynaptic current amplitudes of CA1 hippocampal neurons (Yang et al., 2009). In contrast, larger concentrations of VIP (100 nM) act solely on the PAC1-R in the hippocampus and are dependent on an increase in Ca\(^{2+}\) intracellular levels. Collectively, VIP can regulate cortical function via interactions with VPACRs within cortical circuits.

In the PFC, VIP-positive interneurons are predominately expressed in L1b GABAergic cells expressing the ionotropic serotonin receptor 5HT3a (5HT3aR), as well as cholinergic cells (Tremblay et al., 2016; Anastasiades et al., 2021). Of the 30% of interneurons in the PFC that have 5HT3aR, 40% contain VIP (Tremblay et al., 2016). There are two major subpopulations of VIP interneurons: bipolar and multipolar. Bipolar VIP interneurons are in cortical layers II–VI and heavily concentrated in L2/3 and multipolar VIP cells are populated in the borders of L1/2 and deeper layers (Tremblay et al., 2016). In the cerebral cortex, VIP is radially oriented in bipolar...
interneurons with approximately 30% co-localization with GABA and 80% colocalization with acetylcholine (Magistretti, 1990). The mediiodorsal thalamus drives VIP-positive interneurons localized in L1b to mediate cortical disinhibition via inhibition of SST-positive cells in L2/3 (Anastasiades et al., 2021). Accordingly, VIP contributes to a disinhibitory microcircuits (Anastasiades et al., 2021). Interestingly, VIP enhances the GABA-mediated inhibition of somatosensory neuron activity (Sessler et al., 1991). It is currently unclear clear how VIP peptide transmission coordinates with GABA-mediated inhibition. Furthermore, although VIP interneurons operate locally in cortical columns within the primary sensory cortex, it is unknown whether this same columnar organization holds true for higher-order cortices, such as the PFC species as functional columnar structures have been delineate in primary sensory cortices and differ across species (Fox, 2018).

Cortical modulation of VIP release is regulated by a variety of ion channels and neurotransmitters. In the cortex, Martin and Magistretti (1989a) revealed that K⁺-stimulated VIP release is Ca²⁺-dependent. In a series of experiments, they discovered that Ni²⁺, but not Cd²⁺, nifedipine, diltiazem, or ω-conotoxin, inhibited K⁺-evoked release of VIP, implicating T-type, and not L- and N-type, Ca²⁺ channels (Martin and Magistretti, 1989a). These studies suggest that DCVs containing VIP may recruit different pools of voltage-gated calcium channels, and hence different calcium sources, to trigger exocytosis, relative to vesicles containing fast neurotransmitters. Consistent with localization of VIP-positive neurons to superficial layers of the cortex, in vivo electrical stimulation of cortical superficial layers evoke VIP release ipsilateral but not contralateral to the stimulation site (Wang et al., 1985). VIP release is under the control of excitation and inhibition. Glutamate and kainic acid, as well as disinhibition with GABA antagonism, increase VIP release in cortical slices (Wang et al., 1986; Magistretti, 1990). Furthermore, VIP release is also sensitive to other neuromodulators known to impact cortical circuit dynamics, including norepinephrine, which decreased basal rates of VIP release (Wang et al., 1986). Conversely, carbachol, a cholinergic agonist increased the spontaneous release of cortical VIP (Magistretti, 1990). This is consistent with studies demonstrating that VIP neurons are recruited by external sources of acetylcholine from regions such as the forebrain (Letzkus et al., 2011). Moreover, since VIP is co-expressed with choline acetyltransferase (ChAT) and non-VIP ChAT neurons are found in cortical layer I, acetylcholine derived for local cortical sources may also regulate release of VIP. The majority of VIP-positive/ChAT-positive interneurons in layer I co-release acetylcholine and GABA. However, in the mPFC, ChAT-containing, VIP-lacking cells also release acetylcholine in L1 (Granger et al., 2020). Contradictory results suggest that endogenous opioid systems may regulate VIP release as topical super fusion of MOR, DOR, and KOR agonists had no effect on the spontaneous release of cortical VIP. Interestingly, naloxone, a competitive opioid antagonist, increased VIP efflux. These results suggest that basal opioid tone may be maximally recruited, occluding agonist effects. Some caveats between the effects of in vivo versus in vitro administration of DADL, an opioid peptide, on cortical VIP-LI release has been explored. Wang et al., discovered that applying DADL suppressed K⁺-stimulated cortical VIP-LI release. In contrast, Micevychi et al. (1984), showed that in vitro, cortical application of DADL, had no effect on potassium-evoked VIP-LI release. Lastly, reticular formation stimulation evoked VIP release in vivo, while anesthesia suppresses it (Micevychi et al., 1984), suggesting that VIP release may be linked to arousal. Collectively, these studies provide a framework for future studies to dissect the molecular machinery that underlies the release of VIP.

Vasoactive intestinal peptide interneurons within the PFC modulate behavior either through disinhibition or excitation of cortical neurons. Lee et al. (2013), found the primary vibrissa motor cortex (vM1) strongly projects to VIP interneurons that suppress SST cells. This hyperpolarization of the SST cells by the VIP interneurons allows for voluntary whisking behavior (Lee et al., 2013). Further, PFC ChAT VIP interneurons play a role in maintaining attention as ChAT-VIP interneurons directly excite neurons within different layers of the PFC with fast, cholinergic synaptic transmission (Obermayer et al., 2019). VIP-mediated disinhibition that alleviates dendritic inhibition in cortical pyramidal cells and is also associated with fear learning (Letzkus et al., 2011), amplifies visual processing (Keller et al., 2020). It was discovered that VIP disinhibition of ventral hippocampal inputs to the mPFC cause a decrease in prefrontal responses that results in less open-arm avoidance in the elevated plus maze (Lee et al., 2019). Additionally, a decrease in GCaMP signaling during exploration predicted approaches to the open arms and concluded this circuit helped predict exploratory behavior rather than avoidance (Lee et al., 2019). Together, it is evident that VIP regulates various neural functions.

Although, information regarding the function of VIP interneurons in cortical processing and behavior has continued to accrue in recent years, there is still little known about the effects of VIP release in the PFC. There is limited understanding of the effects of VIP on synaptic transmission or intrinsic excitability of distinct cortical cell types. Given that VIP neurons have unique localization and connectivity patterns within cortical circuits, it is of interest to determine how peptidergic VIP transmission may impact inhibitory interneurons that VIP neurons target for disinhibition versus VIP-sensitive excitatory and inhibitory neurons. VIP has also been implicated in mediating glycogenolysis (Martin and Magistretti, 1989b). VIP's action increases CAMP levels to convert glycogen to glucose 1-phosphate, shifting energy homeostasis through interactions with neurons and glia (Magistretti et al., 1986; Magistretti, 1990). Interestingly, PHI/M, have shown a similar effect of cortical glycogenesis, with lower potencies, implying a role for this mechanism within peptides that share significant similar VIP homology (Magistretti et al., 1986; Magistretti, 1990). Overall, these studies suggest VIP regulates energy substrate accessibility within cortical circuits. VIP's contribution to energy homeostasis in the cortex may further be supported by its role in vasodilation. The role of VIP's effects on cortical microvessels has yet to determined. Further, it is unclear if VIP arising cortically released
neuropeptides or GPCRs embed themselves into local and long-aforementioned viral and genetic approaches to dissect how ligand exists it is possible to integrate these approaches with expressed on different types of molecularly defined cells. In given that neuropeptides and their cognate GPCRs are often sub-populations of neuropeptide and/or GPCR-expressing cells strategies will permit researchers to gain genetic access to throughout the brain. The advent of intersectional genetic receptors within cortical circuits, as well as their terminals tandem with Cre-driver lines to visualize distribution of fluorophores in a Cre-dependent manner can be used in contain neuropeptide receptors. Specifically, viruses expressing genetic access to cell types that release neuropeptides and of a selected neuropeptide or neuropeptide receptor, grant of Cre-driver lines, that express Cre-recombinases in the presence transgenes inherently is binary and does not reflect variations of individual cortical cell types and the neuropeptides and GPCRs found therein (Tasic et al., 2018; Smith et al., 2019; Krienen et al., 2020), will be useful resources for developing specific hypotheses relating to neuropeptide action in PFC circuits. Spatial transcriptomics including multiplexed in situ hybridization, in situ sequencing, and spatial barcoding will be able capture the spatial distribution of various cell populations expressing different neuropeptides and cognate receptors and provide an anatomical context to substantiate scRNA-seq studies (Longo et al., 2021). With increased capabilities to look at many neuropeptides and GPCRs, spatial transcriptomics will begin to unravel the “neuropeptidome” of cortical circuits (Smith et al., 2019). It should be noted that expression of mRNA does not confer functional neuropeptide or GPCR protein expression, highlighting caveats of these aforementioned approaches. Moreover, scRNA-seq experiments may also fail to identify neuropeptide or receptors whose mRNA is expressed in low abundance or localized away from the peri-nuclear space/soma, but is still of physiological relevance. Recently, mice expressing fluorescently labeled opioid receptors have been developed, which allows for mapping of receptors within sub-compartments or projections in defined cell types when coupled with anatomical tracing methods or when molecularly defined cells are tagged (Ehrlich et al., 2019; Chen C. et al., 2020). Careful characterization of novel lines with tagged neuropeptide receptors is necessary to ensure that expression or function of the targeted molecule is not impacted. For example, a thorough characterization of KOR-tdTomato fusion protein mice demonstrated that these mice have increase KOR mRNA expression and binding relative to controls (Chen C. et al., 2020), highlighting the importance of validation experiments and associated considerations as was done in the former study. Notwithstanding this approach will be useful for elucidating endogenous neuropeptide receptor localization and trafficking. Taken together, when used in tandem with physiological, biochemical, and functional anatomical approaches, these approaches provide valuable insight to neuropeptide mRNA expression in diverse cell types and anatomical architecture within tissues.

**Monitoring Neuropeptide Release**

Historically, studies examining peptide release have been limited to acute brain slices or synaptosomal preparations where
Casello et al. Neuropeptides in the Prefrontal Cortex

FIGURE 2 | (A) Anatomical methods in the study of neuropeptides include recombinase driver lines used to gain genetic access to neuropeptide or receptor-expressing cells, spatial transcriptomics, and RNA sequencing. (B) Neuropeptide monitoring methods include genetically encoded GPCR sensors in conjunction with recording methods (e.g., fiber photometry and miniscope), fast-scan cyclic voltammetry (inspired by Roberts and Sombers, 2018), and in vivo microdialysis with mass spectrometry. (C) Methods to study neuropeptide function include nanobody enabled monitoring of neuropeptide receptor states (inspired by Che et al., 2020), genetic modifications (e.g., genetic ablation, editing, or slicing), and the use of photoactivatable neuropeptides. Any of the aforementioned novel approaches can be implemented with established methodologies, such as electrophysiology.
radioimmunoassays and ELISAs have been used to monitor peptide levels in the media. At best, microdialysis procedures have been used to measure fluctuations in extracellular neuropeptide levels in behaving animals. Although these techniques have led to significant advancements in the field, they have low temporal and spatial resolution or are restricted to in vitro conditions. To address these limitations, novel techniques with increased sampling or analytical sensitivity have arisen (Figure 2B). Specifically, fluorescent neuromodulator sensors (Wang et al., 2018; Patriarchi et al., 2019; Peng et al., 2020; Dong et al., 2021; DuFett et al., 2022) provide a means to detect fluctuations in neuropeptide release presence in real time in awake, behaving animals and map sub-cellular sites of neuropeptide release when coupled to high resolution live cell/acute brain slice image. A caveat of genetically encoded fluorescent sensors is that detection of events may be limited to large fluctuations in neuropeptide/receptor activity if the affinity of the neuropeptide for the sensor is not sufficiently high. Additionally, sensors with a very high affinity may display decreased dynamic range or buffer endogenous neuropeptides from acting on their cognate receptors. Lastly, since neuropeptide receptors may bind more than one neuropeptide with high affinity, including unidentified “off-target” actions, it is possible that fluorescent receptor sensor activity may not reflect activity of the neuropeptide of interest. Moreover, electrochemical sensors capitalizing on oxidation/reduction of Tyr in opioid peptides have been employed to monitor putative enkephalin (Roberts and Sombers, 2018). Appropriate controls demonstrating that signals can be detected from endogenously released neuropeptides and the absence of signal upon genetic ablation or inhibition of neuropeptide-expressing neurons will be essential in elucidating the substrates driving fluorescent or electrochemical sensor activity. Neuromodulator receptor-based fluorescent sensors will be useful not only for monitoring neuropeptide transmission in awake-behaving mice but will also be useful for understanding how neuropeptide transmission fits within nuanced architecture and layering of PFC circuits in acute slices and large fields of view in vivo with one or two photon imaging. Further, with increasing palettes of genetically encoded calcium and neurotransmitter sensors, future studies will be able to examine how neuropeptide dynamics fluctuate in relation to neuronal activity or other neurotransmitters. This will provide a comprehensive picture of how sensor activity relates to neuropeptide producing cells or receptor expressing cells. In vivo microdialysis coupled with mass spectrometry allow for simultaneous detection of various extracellular neuropeptides in addition to fast neurotransmitters and monoamines (DiFeliceantonio et al., 2012; Kennedy, 2013; Al-Hasani et al., 2018). As analytical approaches improve, detection of various species of neuropeptides and their metabolic byproducts will provide insight to the actual molecules present in the extra-cellular space and their metabolism. An added benefit is that microdialysis allows for local drug infusion at the sampling site permitting functional pharmacological or chemogenetic studies to be easily integrated. Ultimately, the development of novel techniques to monitor neuropeptide release will provide a platform to monitor cortical neuropeptide dynamics in freely moving behaving animals and closely link neuropeptide dynamics to discrete aspects of behavior in well-designed studies.

Mapping Receptor Function Within Circuits

Although the presence of GPCRs within cortical circuits could previously be identified with histological and in situ hybridization approaches, these approaches do not lend information to GPCR action and kinetics and physiological effects post neuropeptide binding. To identify how neuropeptide GPCRs regulate circuit function, photoactivatable neuropeptides, nanobodies, and advanced pharmacological and immunohistochemical tools are a few of the techniques used to date (Figure 2C). Advancements aimed at increasing specificity and efficacy of pharmacological tools, such as agonists and antagonists of neuropeptide targets, will facilitate work aimed at uncovering the role of neuropeptide action in the PFC. Cell-specific pharmacological approaches are rapidly developing that will aid in the dissection of neuropeptide control of cortical circuitry (Yang et al., 2015; Shields et al., 2017). These approaches provide a significant advantage over conventional pharmacological approaches, which do not discriminate between receptors in distinct circuit elements, in that they provide a means to concentrate or permit the selective gating of ligands to molecularly defined neurons or based on connectivity. Photoactivatable neuropeptides provide a means to determine the kinetics of neuropeptide and GPCR signaling as well as map sub-cellular distribution (Yang et al., 2015). When coupled to multi-photon or focal one-photon uncaging they also uncover spatiotemporally precise actions of GPCRs in distinct compartments of neurons. Genetic methods such as knock-in mouse lines expressing GPCRs fused with fluorescent markers reveal internalization of receptors following behavioral or pharmacological paradigms (Ehrlich et al., 2019; Chen C. et al., 2020). Furthermore, conditional knock-out of neuropeptide or receptor genes from cell populations using Cre-LoxP systems (Kim et al., 2018), short hairpin RNA (Moore et al., 2010), or CRISPR-Cas9 (Ran et al., 2013) will allow manipulation of peptide and receptor expression within cortical circuits. Given that neuropeptides are likely embedded into distinct cell types within PFC circuits that may differ based on molecular definition or connectivity, then expanding availability of recombinase driver lines or complementation of viral approaches will permit for dissection of neuropeptides and their receptors in specific cell types or pathways into or out of the PFC. Finally, changes in GPCR confiramental states in response to activation or deactivation can be studied with various techniques. For instance, nanobodies also can reveal GPCR confiramental states. For example, nanobodies that stabilize distinct ligand-delimited GPCR conformations can report real-time ligand-stabilized GPCR states (Che et al., 2020) and genetically encoded biosensors derived from specific nanobodies can provide precise spatial and temporal resolution of GPCR activation and deactivation (Stoebber et al., 2018). It has been shown that agonist binding induces KOR phosphorylation (Appleyard et al., 1997; Li et al., 2002) and immunohistochemistry can be used to report receptor phosphorylation as a measure of...
neuropeptide-mediated receptor activation (McLaughlin et al., 2004; Lemos et al., 2011; Abraham et al., 2021). Collectively, there has been a rapid expansion of tools to dissect the function of neuropeptides. Ideal studies would use the most appropriate tools needed to address specific questions of how neuropeptides and their receptors relate to circuit function and/or behavior, keeping in mind strengths and caveats associated with each approach when designing studies and selecting tools to employ. In practice, dissection of the role of neuropeptides and their receptors in PFC circuits will require the use of multiple converging, complementary approaches, and inclusion of controls and validation studies, where appropriate. When coupled to cutting-edge ex vivo and in vivo electrophysiological, anatomical, in vivo imaging, and well-designed behavioral studies, these ensembles of emerging tools will be crucial for significant advances in our understanding the role of neuropeptides in intercellular communication in cortical circuits.

CONCLUSION

In this review we provide a comprehensive examination and discussion of the literature on neuropeptide modulation of cortical circuitry, with an emphasis on the PFC. To date, knowledge of neuropeptide action is largely limited to subcortical brain structures. Expanding the field’s knowledge on neuropeptide action in the PFC and how neuropeptide systems regulate information processing in cortical circuits provides paths to develop therapeutic targets for the treatment of neuropsychiatric disorders. Further, increased knowledge PFC organization and function will provide a greater context for future findings on neuropeptide function. Together, investigating PFC networks and neuropeptide regulation of those circuits while capitalizing on novel approaches will help elucidate contributing factors in neuropsychiatric disorders and novel treatments for these disorders.

AUTHOR CONTRIBUTIONS

All authors wrote, edited, and approved the final manuscript.

FUNDING

This work was supported by the National Institute of Mental Health Intramural Research Program, the NIH Center for Compulsive Behavior Post-doctoral Fellowship (HY and RJF), a NIGMS Post-Doctoral Research Associate Training fellowship (RJF), and a NARSAD Young Investigator Award (HT).

ACKNOWLEDGMENTS

We would like to thank members of the Tejeda Laboratory for helpful discussions. Images created with Biorender.com.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fncir.2022.796443/full#supplementary-material

REFERENCES

Abate, P., Reyes-Guzman, A. C., Hernandez-Fonseca, K., and Mendez, M. (2017). Prenatal ethanol exposure modifies locomotor activity and induces selective changes in Met-enk expression in adolescent rats. Neuropeptides 62, 45–56. doi: 10.1016/j.npep.2016.11.006
Abbas, A. I., Sundiang, M. J. M., Henoch, B., Morton, M. P., Bolkan, S. S., Park, A. J., et al. (2018). Somatostatin interneurons facilitate hippocampal-prefrontal synchrony and prefrontal spatial encoding. Neuron 100, 926.e3–939.e3. doi: 10.1016/j.neuron.2018.09.029
Abraham, A. D., Casello, S. M., Schattauer, S. S., Wong, B. A., Mizuno, G. O., Mahe, K., et al. (2021). Release of endogenous dynorphin opioids in the prefrontal cortex disrupts cognition. Neuropsychopharmacology 46, 2330–2339. doi: 10.1038/s41386-021-01168-2
Adesnik, H., and Naka, A. (2018). Cracking the function of layers in the sensory cortex. Neuron 100, 1028–1043. doi: 10.1016/j.neuron.2018.05.032
Adrian, T., Allen, J., Bloom, S., Ghati, M., Rossor, M., Roberts, G., et al. (1983). Neuropeptide Y distribution in human brain. Nature 306, 584–586.
Aizawa-Abe, M., Ogawa, Y., Masuzaki, H., Ebihara, K., Satoh, N., Iwai, H., et al. (2000). Pathophysiological role of leptin in obesity-related hypertension. J. Clin. Invest. 105, 1243–1252. doi: 10.1172/JCI8341
Al-Hasani, R., Wong, J. T., Mabrouk, O. S., McCall, J. G., Schmitz, G. P., Porter, Stranksy, K., et al. (2018). In vivo detection of optically-evoked opioid peptide release. eLife 7:e36520. doi: 10.7554/eLife.36520
Alvarez-Bolado, G., Fairen, A., Douglass, J., and Naranjo, J. R. (1990). Expression of the prodynorphin gene in the developing and adult cerebral cortex of the rat: an in situ hybridization study. J. Comp. Neurol. 300, 287–300. doi: 10.1002/cne.903000302
Anastasiades, P. G., Collins, D. P., and Carter, A. G. (2021). Mediodorsal and ventromedial thalamic engage distinct L1 circuits in the prefrontal cortex. Neuron 109, 314.e4–330.e4. doi: 10.1016/j.neuron.2020.10.031
Aoki, C., and Pickel, V. M. (1989). Neuropeptide Y in the cerebral cortex and the caudate-putamen nucleus: ultrastructural basis for interactions with GABAergic and non-GABAergic neurons. J. Neurosci. 9, 4333–4354. doi: 10.1523/JNEUROSCI.09-12-04333.1989
Appleyard, S. M., Patterson, T. A. J., Jin, W., and Charkin, C. (1997). Agonist-induced phosphorylation of the kappa-opioid receptor. J. Neurochem. 69, 2405–2412. doi: 10.1046/j.1471-4159.1997.69062405.x
Arnsten, A. F. (2015). Stress weakens prefrontal networks: molecular insults to higher cognition. Nat. Neurosci. 18, 1376–1385. doi: 10.1038/nn.4087
Augustine, F., Rajendran, S., and Singer, H. S. (2020). Cortical endogenous opioids and their role in facilitating repetitive behaviors in deer mice. Behav. Brain Res. 379:112317. doi: 10.1016/j.bbr.2019.112317
Augusto, E., and Gambino, F. (2019). Can NMDA spikes dictate computations of local networks and behavior? Front. Mol. Neurosci. 12:238. doi: 10.3389/fnmol.2019.00238
Bacci, A., Huguenard, J. R., and Prince, D. A. (2002). Differential modulation of synaptic transmission by neuropeptide Y in rat neocortical neurons. Proc. Natl. Acad. Sci. 99, 17125–17130. doi: 10.1073/pnas.012481899
Baldwin, G. S., Patel, O., and Shulkes, A. (2010). Evolution of gastrointestinal hormones: the cholecystokinin/gastrin family. Curr. Opin. Endocrinol. Diabetes Obes. 17, 77–88. doi: 10.1097/MED.0b013e328334e535
Ballaz, S. J., Bourin, M., Akil, H., and Watson, S. J. (2020). Blockade of the endocannabinoid system and the cannabinoid CB1 receptor prevents the normalization of anxiety levels in the rat. Prog. Neuropsychopharmacol. Biol. Psychiatry 96:109761. doi: 10.1016/j.pnpbp.2019.109761
Bals-Kubiš, R., Abletiner, A., Herz, A., and Shippenberg, T. S. (1993). Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J. Pharmacol. Exp. Ther. 264, 489–495.

Baraban, S. C., and Tallent, M. K. (2004). Interneuron diversity series: interneuronal neuropeptide–endogenous regulators of neuronal excitability. Trends Neurosci. 27, 135–142. doi: 10.1016/j.tins.2004.01.008

Barnett, P. (2003). Somatostatin and somatostatin receptor physiology. Endocrine 20, 25–264. doi: 10.1385/endo:20:3:255

Bazov, I., Sarkisyan, D., Kononenko, O., Watanabe, H., Taqi, M. M., Stalhandske, J. P., and Burbach, J. P. (2011). What are neuropeptides? J. Neurosci. 31, 160–166. doi: 10.1016/j.brainres.2011.05.038

Besson, M., Vidal, M., and Debon, M. C. (1973). The distribution of cholecystokinin immunoreactivity in rat brain. Alcohol. Clin. Exp. Res. 7, 617–620. doi: 10.1177/014626727300700204

Biedenbender, J., Sulser, F., Schouten, J., and Siesjö, B. K. (1986). The specificity of microdialysis in the in vivo monitoring of neurotransmitters and neuropeptides. Trends Neurosci. 9, 136–144. doi: 10.1016/0165-6147(86)90164-5

Bolhuis, E. J., and van der Graaf, Y. G. (2012). The endogenous opiate system in the human brain: an update. Neurosci. Biobehav. Rev. 36, 346–361. doi: 10.1016/j.neubiorev.2011.09.002

Bonanno, G., Parodi, B., Cafaggi, S., and Raiteri, M. (1991). Somatostatin release from rat hippocampal neurons maintained in vitro. Neurosci. Lett. 125, 125–129. doi: 10.1016/0304-3940(91)90148-t

Brady, S. C., and Tallent, M. K. (2005). Interneuron diversity series: interneuronal neuropeptide–endogenous regulators of neuronal excitability. Trends Neurosci. 28, 1154–1161. doi: 10.1016/j.tins.2005.08.004

Brown, T. L., et al. (2014). The role of cannabinoid 1 receptor expressing interneurons in the dopaminergic reward system of human alcoholics. Mol. Psychiatry 20, 255–264. doi: 10.1038/mp.2014.73

Browne, C. A., Jacobson, M. L., and Lucki, I. (2020). Novel targets to treat depression: opioid-based therapeutics. Harv. Rev. Psychiatry 28, 40–59. doi: 10.1097/HRP.0000000000000242

Budde, M., and van der Meché, F. G. (2011). The role of neuropeptides in the prefrontal cortex. Neuron 70, 137–147. doi: 10.1016/j.neuron.2011.05.012

Butelman, E. R., Yufner, V., and Kreek, M. J. (2012). kappa-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends Neurosci. 35, 587–596. doi: 10.1016/j.tins.2012.05.005

Buzsáki, G. (2002). Neuronal oscillations in the brain. Nat. Rev. Neurosci. 3, 78–87. doi: 10.1038/nrn666

Cahill, E., Pascoli, V., Trifillieff, P., Savoldi, D., Kappes, V., Luscher, C., et al. (2014). D1/GluN1 complexes in the striatum integrate dopamine and glutamate signalling to control synaptic plasticity and cocaine-induced responses. Mol. Psychiatry 19, 1295–1304. doi: 10.1038/mp.2014.73

Carlen, M. (2017). What constitutes the prefrontal cortex? Science 358, 478–482. doi: 10.1126/science.aan886

Castillo, P. E., Salin, P. A., Weisskopf, M. G., and Nicoll, R. A. (1996). Characterizing the site and mode of action of dynorphin at hippocampal mossy fiber synapses in the guinea pig. J. Neurosci. 16, 5942–5950. doi: 10.1523/ JNEUROSCI.16-19-05942.1996

Castro, D. C., and Bruchas, M. R. (2019). A motivational and neuropeptidergic hub: anatomical and functional diversity within the nucleus accumbens shell. Neuron 102, 529–552. doi: 10.1016/j.neuron.2019.03.003

Caulfield, D. E., and Lovenberg, T. W. (1983). Corticotrophin-releasing factor: from molecular biology to drug design. Trends Pharmacol. Sci. 17, 166–172. doi: 10.1016/0165-6147(96)81594-x

Chan, R. K., Vale, W. W., and Sawchenko, P. E. (2000). Paradoxical activation effects of a corticotropin-releasing factor-binding protein “lignad inhibitor” in rat brain. Neuroscience 101, 115–129. doi: 10.1016/s0306-4522(00)00322-5

Chang, J. W., Lee, A. S., and Chang, W. H. (2017). The role of neuropeptides in the modulation of binge eating disorder. Trends Neurosci. 40, 229–245. doi: 10.1016/j.tins.2017.03.004

Chavkin, C. (2000). Dynorphins are endogenous opioid peptides released from granule cells to act neurohormonally and inhibit excitatory neurotransmission in the hippocampus. Prog. Brain Res. 125, 363–367. doi: 10.1016/S0079-1213(00)25025-5

Chavkin, C., Bakhit, C., Weber, E., and Bloom, F. E. (1983). Relative contents of opioid receptor subtypes in the mouse brain. J. Neurochem. 41, 285–312. doi: 10.1111/j.1365-2876.1981.tb05590.x

Cherny, S. A., and Weinberger, D. R. (2011). What are neuropeptides? Methods Mol. Biol. 789, 1–36. doi: 10.1007/978-1-61779-310-3_1

Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Greenlick, M. R., Izzo, J. L., et al. (2003). The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289, 2560–2572. doi: 10.1001/jama.289.19.2560

Chomiatakis, K., and Karavas, E. (2015). Neuropeptides in cognitive and affective disorders: the role of neuropeptide Y. J. Biomed. Biotech. 2015, 1–9. doi: 10.1155/2015/492380403

Choulakian, T., and Tong, J. (2010). Corticotropin-releasing factor: from molecular biology to drug design. Trends Pharmacol. Sci. 31, 457–463. doi: 10.1016/j.tips.2010.01.001

Chou, M., Li, R., and Xu, J. (2013). The role of neuropeptide Y in the development and progression of cerebral ischemia. J. Neurosci. Res. 91, 1868–1877. doi: 10.1002/jnr.23656

Chuang, C., and Goldstein, A. (1981). Specific receptor for the opioid peptide dynorphin: structure–activity relationships. Proc. Natl. Acad. Sci. U.S.A. 78, 6543–6547. doi: 10.1073/pnas.78.10.6543
Dautzenberg, F. M., and Hauger, R. L. (2002). The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol. Sci. 22, 532–537. doi: 10.1016/j.tips.2012.08.014

Dodd, J., and Kelly, I. S. (1981). The actions of cholecystokinin and related peptides on pyramidal neurones of the mammalian hippocampus. Brain Res. 205, 337–350. doi: 10.1016/0006-8993(83)90344-9

Dong, A., He, K., Dudok, B., Farrell, J. S., Guan, W., Liput, D. J., et al. (2021). A fluorescent sensor for spatiotemporally resolved imaging of endocannabinoid dynamics in vivo. Nat. Biotechnol. [Epub ahead of print]. doi: 10.1038/s41587-021-01074-4

Dournaud, P., Gu, Y. Z., Schonbrunn, A., Mazella, J., Tannenbaum, G. S., and Beaudet, A. (1996). Localization of the somatostatin receptor SST2A in rat brain using a specific anti-peptide antibody. J. Neurosci. 16, 4468–4478. doi: 10.1523/JNEUROSCI.16-14-04668.1996

Drake, C., Terman, G. W., Simmons, M. L., Milner, T. A., Kunkel, D. D., Schwartzkroin, P. A., et al. (1994). Dynorphin opioids present in dentate granule cells may function as retrograde inhibitory neurotransmitters. J. Neurosci. 14, 3736–3750. doi: 10.1523/JNEUROSCI.14-06-03736.1994

D’Souza, R. D., and Burkhalter, A. (2017). A laminar organization for selective cortico-cortical communication. Front. Neuroanat. 11:71. doi: 10.3389/fnana.2017.00071

Duffett, L., Kosar, S., Pannillo, M., Viberi, B., Bracey, E., Zych, A. D., et al. (2022). A genetically encoded sensor for in vivo imaging of orexin neurotropes. Nat. Methods 19, 231–241. doi: 10.1038/s41592-021-01390-2

Dumont, Y., Martel, J.-C., Hoebeke, P., and Quirion, R. (1992). Neuropeptide Y and neuropeptide Y receptor subtypes in brain and peripheral tissues. Prog. Neurobiol. 38, 125–167. doi: 10.1016/0079-6194(92)90038-g

Dunlop, B. W., Rothbaum, B. O., Binder, E. B., Duncan, E., Harvey, P. D., Jovanovic, T., et al. (2014). Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. Trials 15:240. doi: 10.1186/1745-6215-15-240

Duque-Diaz, E., Diaz-Cabiale, Z., Narvaez, J. A., and Covenas, R. (2017). Mapping of enkephalin and adrenocorticotropic hormone in the squirrel monkey brainstem. Anat. Sci. Int. 92, 275–292. doi: 10.1007/s12565-016-0333-3

Dvorakova, M. C., Kružliak, P., and Babkin, S. W. (2014). Role of neuropeptides in cardiomyopathies. Peptides 61, 1–6. doi: 10.1016/j.peptides.2014.08.004
Hillhouse, E. W., and Grammatopoulos, D. K. (2006). The molecular mechanisms

Heldin, C. H., Lu, B., Evans, R., and Gutkind, J. S. (2016). Signals and receptors.

Heilig, M., Söderpalm, B., Engel, J. A., and Widerlöv, E. (1989). Centrally

Hendry, S., Jones, E., DeFelipe, J., Schmechel, D., Brandon, C., and Emson, P. (1984). Neuropeptide-containing neurons of the cerebral cortex are also

Herkenham, M. (1987). Mismatches between neurotransmitter and receptor

Hook, V., Funkelstein, L., Lu, D., Bark, S., Wegryn, J., and Hwang, S. (2008). Proteases for processing proenkephalins into peptide neurotransmitters and hormones. Annu. Rev. Pharmacol. Toxicol. 48, 393–423. doi: 10.1146/annurev.pharmtox.48.113006.094812

Hofman, G. D., Volk, D. W., Bazmi, H. H., Li, S., Sampson, A. R., and Lewis, D. A. (2015). Altered cortical expression of GABA-related genes in schizophrenia: illness progression vs developmental disturbance. Schizophr. Biol. 41, 180–191. doi: 10.1093/schbul/5b178

Hokfelt, T., Broberger, C., Xu, Z. Q., Sergeyev, V., Ubink, R., and Diez, M. (2000). Neuropeptides—an overview. Neuropharmacology 39, 1337–1356. doi: 10.1016/s0029-8081(00)00101-9

Holaday, J. W. (1983). Cardiovascular effects of endogenous opiate systems.

Husum, H., Vasquez, P. A. J., and Mathé, A. A. (2001). Changed concentrations of tachykinins and neuropeptide Y in brain of a rat model of depression: lithium treatment normalizes tachykinins. Neuropeychopharmacology 24, 183–191. doi: 10.1016/s0898-1339(00)00198-6

Hwa, L. S., Neira, S., Pina, M. M., Pati, D., Calloway, R., and Kast, T. L. (2019). Predator odor increases avoidance and glutamatergic synaptic transmission in the prelimbic cortex via corticotropin-releasing factor receptor 1 signaling. Neuropsychopharmacology 44, 776–775. doi: 10.1016/s0893-8519(17)32472-6

Ibrahim, L. A., Schuman, B., Bandler, R., Rudy, B., and Fishell, G. (2020). Mining the jewels of the cortex’s crowning mystery. Curr. Opin. Neurobiol. 63, 154–161. doi: 10.1016/j.conb.2020.03.005

Iggo, R., Fujimori, N., Ito, T., Nakamura, T., Oono, T., Nakamura, K., et al. (2011). Vasoactive intestinal peptide (VIP) and VIP-receptors: elucidation of structure and function for therapeutic applications. Int. J. Clin. Med. 02, 500–508. doi: 10.4236/ijcm.2011.260804

Ingram, S. M., Krause, R. G. II, Baldino, F. J., Sleen, L. C., and Lewis, M. E. (1989). Neuronal localization of cholecystokinin mRNA in the rat brain by using in situ hybridization histochemistry. J. Comp. Neurol. 287, 260–272. doi: 10.1002/j.cn.20087209

Iwasa, C., Kuzumaki, N., Suda, Y., Kagawa, R., Oka, Y., Hattori, N., et al. (2019). Reduced expression of somatostatin in GABAergic interneurons derived from induced pluripotent stem cells of patients with parkin mutations. Mol. Brain 12.5. doi: 10.1186/s13041-019-0426-7

Ieri, A., and Bhattachar, S. (2007). Corticotropin-releasing hormone receptors in the medial prefrontal cortex regulate hypothalamic-pituitary-adrenal activity and anxiety-related behavior regardless of prior stress experience. Brain Res. 1186, 212–223. doi: 10.1016/j.brainres.2007.10.007

James, I. F., Fischli, W., and Goldstein, A. (1984). Opioid receptor selectivity of dynorphin gene products. J. Pharmacol. Exp. Ther. 228, 88–93.

Jiang, S. Z., Winters, S., Dahlke, S. P., Loane, K., Drossel, G., Xu, W., et al. (2021). Cocaine-dependent acquisition of locomotor sensitization and conditioned place preference requires d1 dopaminergic signaling through a cyclic AMP, NCS-RapgeF2, ERG, and Egr-1/Zeit6 pathway. J. Neurosci. 41, 711–725. doi: 10.1523/NEUROSCI.1497-20.2020

Jiang, X., Shen, S., Cadwell, C. R., Berens, P., Sinz, F., Ecker, A. S., et al. (2015). Principles of connectivity among morphologically defined cell types in adult neocortex. Science 350:aae462. doi: 10.1126/science.aac462

Jimenez-Vasquez, P. A., Diaz-Cabale, Z., Caberlotto, L., Bellido, L., Overstreet, D., Fuxe, K., et al. (2007). Electroconvulsive stimuli selectively affect behavior and neuropeptide Y (NPY) and NPY Y(1) receptor gene expressions in hippocampus and hypothalamus of Finsiders Sensitive Line rat model of depression. Eur. Neuropsychopharmacol. 17, 298–308. doi: 10.1016/j.euroneuro.2006.06.011

Johnson, A. H. (1998). Phyllogeny-of-the-cholecystokinin-gastrin. Front. Neuroendocrinol. 19:163. doi: 10.1016/j.fner.1997.0163

Johnson, S. W., and North, R. A. (1992). Opioids excite dopamine neurons by hyperpolarization of local interneurons. J. Neurosci. 12, 483–488. doi: 10.1523/JNEUROSCI.12-02-00483.1992

Karagannis, A., Gallopip, T., Davide, C., Battaglia, D., Geoffroy, H., Rossier, J., et al. (2009). Classification of NPY-expressing neocortical interneurons. J. Neurosci. 29, 3642–3659. doi: 10.1523/JNEUROSCI.0058-09.2009

Kash, T. L., Pleil, K. E., Marcinkiewicz, C. A., Lowery-Gionta, E. G., Crowley, N., Mazzone, C., et al. (2015). Neuropeptide regulation of signaling and behavior in the BNST. Mol. Cells 38, 1–13. doi: 10.14348/mocells.2015.2261

Keckés, M., Henn-Mike, N., Agócs-Laboda, Á, Szőcs, S., Petyók, Z., and Varga, C. (2020). Somatostatin expressing GABAergic interneurons in the medial entorhinal cortex preferentially inhibit layer III-V pyramidal cells. Commun. Biol. 3, 1–13. doi: 10.1038/s42003-020-01496-x

Kehne, J., and De Lombaert, S. (2002). Non-peptidic CRF1 receptor antagonists for the treatment of anxiety, depression and stress disorders. Curr. Drug Targets CNS Neurol. Disord. 1, 467–493. doi: 10.2174/1568070723339049

Keller, A. J., Roth, M. M., and Scanziani, M. (2020). Feedback generates a second receptive field in neurons of the visual cortex. Neuron 208, 1–13. doi: 10.1016/j.neuron.2020.02.008

Kennedy, A., Ashina, K., Hooper, E., Inagaki, H., Jung, Y., Lee, H., et al. (2014). Internal states and behavioral decision-making: toward an integration of emotion and cognition. Cold Spring Harb. Symp. Quant. Biol. 79, 199–210. doi: 10.1101/cshperspect.a015221

Kennedy, R. T. (2013). Emerging trends in in vivo neurochemical monitoring by microdialysis. Curr. Opin. Chem. Biol. 17, 860–867. doi: 10.1016/j.cbpa.2013.06.012

Ketchesin, K. D., Huang, N. S., and Seasholtz, A. F. (2017). Cell type-specific expression of corticotropin-releasing hormone-binding protein in GABAergic
interneurons in the prefrontal cortex. Front. Neuroanat. 11:90. doi: 10.3389/fnana.2017.00090
Khachaturian, H., Lewis, M. E., Haber, S. N., Houghten, R. A., Akil, H., and Watson, S. J. (1985). Prodynorphin peptide immunocytochemistry in rhesus monkey brain. Peptides (6 Suppl 2), 155–166. doi: 10.1016/S0196-9718(85)90149-4
Kim, H., Kim, M., Im, S. K., and Fang, S. (2018). Mouse Cre-LoxP system: general principles to determine tissue-specific roles of target genes. Lab. Anim. Res. 34, 147–159. doi: 10.5652/lar.2018.34.4.1417
Kim, S. M., Su, C. Y., and Wang, J. W. (2017). Neuromodulation of innate behaviors in Drosophila. Annu. Rev. Neurosci. 40, 327–348. doi: 10.1146/annurev-neuro-072116-031558
Kim, T., Gondre-Lewis, M. C., Arnaoutova, I., and Loh, Y. P. (2006). Dense-core secretory granule biogenesis. Physiology 21, 124–133. doi: 10.1152/physiol.
00043.2005
Kim, Y. S., Anderson, M., Park, K., Zheng, Q., Agarwal, A., Gong, C., et al. (2016). Coupled activation of primary sensory neurons contributes to chronic pain. NeuroReport 91, 1085–1096. doi: 10.1177/1047328X16644430
Klapstein, G. J., and Colmers, W. F. (1993). On the sites of presynaptic inhibition in pyramidal neurons with subregional selectivity. J. Neurophysiol. 6(Suppl. 2), 155–166. doi: 10.1016/0196-9718(85)90149-4
Koenigs, M., and Grafman, J. (2009). Posttraumatic stress disorder: the role of the medial prefrontal cortex and amygdala. Neuroscientist 15, 540–548. doi: 10.1177/1073858409333072
Koo, G. F. (2010). The role of CRF and CRF-related peptides in the dark side of addiction. Brain Res. 1314, 3–14. doi: 10.1016/j.brainres.2009.11.008
Kienzen, F. M., Goldman, M., Zhang, Q., del Rosario, R. C. H., Florio, M., Machold, R., et al. (2020). Innovations present in the primate interneuron repertoire. Nature 586, 262–269. doi: 10.1038/s41586-020-2781-z
Kropotova, E. S., Ilevse, I. S., Karpenko, M. N., and Mosevitsky, M. I. (2020). Design of enkephalin modifications protected from brain extracellular peptides providing long-term analgesia. Bioorg. Med. Chem. 28:115184. doi: 10.1016/j.bmc.2019.115184
Krutlich, L., Dharwal, A. P., and McMinn, S. M. (1968). Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 83, 783–790. doi: 10.1210/endo-83-4-783
Kumar, U. (2005). Expression of somatostatin receptor subtypes (SSTR1-5) in Alzheimer’s disease brain: an immunohistochemical analysis. Neuroscience 134, 525–538. doi: 10.1016/j.neuroscience.2005.04.001
Lamberts, S. W., van der Lely, A. J., de Herder, W. W., and Hofland, L. J. (1996). Octreotide. N. Engl. J. Med. 334, 246–254. doi: 10.1056/NEJM19961233043440
Larhammar, D., and Salaneck, E. (2004). Molecular evolution of NPY receptor family genes. Mol. Biol. Evol. 22, 627–644. doi: 10.1093/molbev/msu050
Le Merre, P., de Solis, C. A., Boyle, L. M., Bock, T., Lofaro, O. M., Buss, E. W., et al. (2019). VIP interneurons contribute to avoidance behavior by independently attenuating acquisition and consolidation of associative memories. Behav. Brain Res. 323, 1–10. doi: 10.1016/j.bbr.2017.01.032
Lee, T. I., et al. (2019). Phosphoproteomic approach for agonist-specific signaling between human and rat kappa-opioid receptors expressed in Chinese hamster ovary cells. Mol. Pharmacol. 61, 73–84. doi: 10.1124/mol.61.1.73
Li, Q., Dong, C., Li, W., Bu, W., Wu, J., and Zhao, W. (2014). Neuropeptide Y protects cerebral cortical neurons by regulating microglial immune function. Neural Regener. Res. 9:959. doi: 10.1007/s11357-013-13540
Li, W., Papilloud, A., Lozano-Montes, L., Zhao, N., Ye, X., Zhang, X., et al. (2018). Stress impacts the regulation neuropeptides in the rat hippocampus and prefrontal cortex. Proteomics 18:e1700408. doi: 10.1002/pmic.201700408
Liberzon, I., Taylor, S. F., Phan, K. L., Britton, J. C., Fig, L. M., Bueller, J. A., et al. (2007). Altered central micro-opioid receptor binding after psychological trauma. Biol. Psychiatry 61, 1030–1038. doi: 10.1016/j.biopsych.2006.06.021
Liguere-Leczner, M., Urban-Ciecko, J., and Kossut, M. (2016). Somatostatin and somatostatin-containing neurons in shaping neuronal activity and plasticity. Front. Neural Circ. 10:48. doi: 10.3389/fncir.2016.00048
Lin, L. C., and Sibille, E. (2015). Somatostatin, neuronal vulnerability and behavioral emotionality. Mol. Psychiatry 20, 377–387. doi: 10.1038/mp.2014.184
Lin, S., Boey, D., Lee, N., Schwarzer, C., Sainsbury, A., and Herzog, H. (2006). Distribution of prodynorphin mRNA and its interaction with the NPY system in the mouse brain. Neuroreport 17, 105–108. doi: 10.1097/00001072-200601110-00012
Liu, J., Liu, Y. T., DiMattio, K. M., Chen, C., Huang, P., Gentile, T. A., et al. (2019). Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in kappa opioid aversion. Neuropsychopharmacology 44, 939–949. doi: 10.1038/s41386-018-0153-0
Liu, R. J., Ota, K. T., Dutheil, S., Duman, R. S., and Aghajanian, G. K. (2015). Ketamine strengthens CRF-activated amygdala inputs to basal diencephalon in mPFC layer V pyramidal cells in the prelimbic but not infralimbic subregion, a key suppressor of stress responses. Neuropsychopharmacology 40, 2066–2075. doi: 10.1038/npp.2015.70
Liu, X., Dimidchits, J., Fishell, G., and Carter, A. G. (2020). Hippocampal inputs engage CCK+ interneurons to mediate endocannabinoid-modulated feed-forward inhibition in the prefrontal cortex. Elife 9:e55267. doi: 10.7554/eLife.55267
Loh, R., Collins, S., and Galvez, R. (2017b). Neocortical prodynorphin expression is transiently increased with learning: implications for time- and learning-dependent neocortical kappa opioid receptor activation. Behav. Brain Res. 335, 145–150. doi: 10.1016/j.bbr.2017.08.015
Loh, R., Rau, L., Ahijaz, A., Wu, K., and Galvez, R. (2017a). Antagonizing the different stages of kappa opioid receptor activation selectively and independently attenuates acquisition and consolidation of associative memories. Behav. Brain Res. 323, 1–10. doi: 10.1016/j.bbr.2017.01.032
Longo, S. K., Guo, M. G., Ji, A. L., and Khavari, P. A. (2021). Integrating single-cell and spatial transcriptomics to elucidate intercellular tissue dynamics. Nat. Rev. Genet. 22, 627–644. doi: 10.1038/s41576-021-00370-8
Lukomska, A., Dobrzanski, G., Liguere-Leczner, M., and Kossut, M. (2020). Somatostatin receptors (SSTR1-5) on inhibitory interneurons in the barrel cortex. Brain Struct. Funct. 225, 387–401. doi: 10.1007/s00381-019-02020-9
Maarrawi, J., Peyron, R., Mertens, P., Costes, N., Magnin, M., Sindou, M., et al. (2007a). Differential brain opioid receptor availability in central and peripheral neuropathic pain. Pain 127, 183–194. doi: 10.1016/j.pain.2006.10.013
Mathé, A. A., Michaneck, M., Berg, E., Charney, D. S., and Murrough, J. W. (2011). Induction of hyperphagia in a model of hypothalamic obesity in rats. J. Neurosci. 31, 3249–3260. doi: 10.1523/JNEUROSCI.1678-10.2011

Mena, J. D., Selleck, R. A., and Baldo, B. A. (2013). Mu-opioid stimulation in rat prefrontal cortex engages hypothalamic orexin/hypocretin-containing neurons, and reveals dissociable roles of nucleus accumbens and hypothalamus in cortically driven feeding. J. Neurosci. 33, 18540–18552. doi: 10.1523/JNEUROSCI.3233-12.2013

Meng, F., Xie, G. X., Thompson, R. C., Mansour, A., Goldstein, A., Watson, S. J., et al. (1993). Cloning and pharmacological characterization of a rat kappaoi receptor. Proc. Natl. Acad. Sci. U.S.A. 90, 9954–9958. doi: 10.1073/pnas.90.21.9954

Meng, Q. Y., Chen, X. N., Tong, D. L., and Zhou, J. N. (2011). Stress and glucocorticoids regulated corticotropin releasing factor in rat prefrontal cortex. Mol. Cell Endocrinol. 342, 54–63. doi: 10.1016/j.mce.2011.05.035

Menlo, R. (2004). Cell-surface peptides. Int. Rev. Cytol. 235, 165–213. doi: 10.1016/S0074-7696(04)35004-7

Merchanthaler, I., Maderdrut, J. L., Cianchetta, P., Shughrze, P., and Bronstein, D. (1997). In situ hybridization histochemical localization of dynorphin messenger RNA in the central nervous system of the rat. J. Comp. Neurol. 384, 211–232. doi: 10.1002/sic.1096-9861(19970728)384:2<211:aaid-cnu>3.0.co;2-4

Micevych, P. E., Yakh, T. L., Go, V. W., and Finklestein, J. A. (1985). Effect of opiates on the release of cholecystokinin from in vitro hypothalumus and frontal cortex of Zucker lean (Fa/) and obese (fa/fa) rats. Brain Res. 337, 382–385. doi: 10.1016/0006-8993(85)90800-0

Micevych, P. E., Go, V. L., and Yakh, T. L. (1984). Simultaneous measurement of cholecystokinin- and vasoactive intestinal polypeptide like immunoreactivity from cat frontal cortex in vitro: effect of morphine and D-Ala2-D-Leu5-enkephalin. Brain Res. 291, 55–62. doi: 10.1016/0006-9993(84)90560-4

Mickey, B. J., Zhou, Z., Heitzeig, M. M., Heinz, E., Hodgkinson, C. A., Hsu, D. T., et al. (2011). Emotion processing, major depression, and functional genetic variation of neuropeptide Y. Arch. Gen. Psychiatry 68, 158–166. doi: 10.1001/archgenpsychiatry.2010.197

Millard, M. R., Pitman, R. K., Ellis, C. B., Gold, A. L., Shin, L. M., Lasko, N. B., et al. (2009). Neurobiological basis of failure to recall extinction memory in posttraumatic stress disorder. Biol. Psychiatry 66, 1075–1082. doi: 10.1016/j.biopsych.2009.06.026

Millan, M. A., Samra, A. B., Wynn, P. C., Catt, K. J., and Aguilar, G. (1987). Receptors and actions of corticotropin-releasing hormone in the primate pituitary gland. J. Clin. Endocrinol. Metab. 64, 1036–1041. doi: 10.1210/jcem-64-5-1036

Millman, D. J., Ocker, G. K., Calcéon, S., Kato, I., Larkin, J. D., Lee, E. K., et al. (2020). VIP interneurons in mouse primary visual cortex selectively enhance responses to weak but specific stimuli. eLife 9, e51380. doi: 10.7554/eLife.51380

Minamino, N., Kangawa, K., Fukuda, A., Matsuo, H., and Iagarashi, M. (1980). Structure of rat PYY mRNA: identification of a natural rat mRNA splice-variant that is downregulated in the hypothalamus and the prefrontal cortex of a depression-like model. Peptides 4, 46–50. doi: 10.1016/0191-9913(84)90033-3

Mola, J., and Cox, B. M. (2012). Subcellular localization of immune-reactive dynorphin and vasopressin in rat pituitary and hypothalamus. Life Sci. 90, 1765–1768. doi: 10.1016/j.lfs.2012.04.005

Molosh, A. I., Sajdyk, T. J., Truitt, W. A., Oxford, G. S., and Shekhar, A. (2013). NPY Y1 receptors differentially modulate GABAergic and NMDA receptors in the rat hippocampus. J. Neurosci. 33, 2320–2331. doi: 10.1523/JNEUROSCI.2439-12.2013

Mora, C. B., Guthrie, E. H., Huang, M. T., and Taxman, D. J. (2010). Short hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown. Methods 50, 238–254. doi: 10.1016/j.ymeth.2010.05.003

Morino, P., Herrera-Marschitz, M., Castel, M. N., Ungerstedt, U., Varro, A., Dockray, G., et al. (1994). Cholecystokinin un cortico-striatal neurons in the rat immunochemical studies at the light and electron microscopical level. Eur. J. Neurosci. 6, 681–692. doi: 10.1111/j.1465-9968.1994.tb00980.x
Mucha, R. F., and Herz, A. (1985). Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning. *Psychopharmacology* 86, 274–280. doi: 10.1007/BF00342215

Mueller, A. L., Kunkel, D. D., and Schwartzkroin, P. A. (1986). Electrophysiological actions of somatostatin (SRIF) in hippocampus: an in vitro study. *Cell. Mol. Neurobiol.* 6, 363–379. doi: 10.1007/BF00711406

Murray, E. A., and Fellows, L. K. (2021). Prefrontal cortex interactions with the amygdala in primates. *Neuropsychopharmacology* 47, 163–179. doi: 10.1038/s41386-021-01128-w

Naka, A., Veit, J., Shababo, B., Chance, R. K., Risso, D., Stafford, D., et al. (2019). Complementary networks of cortical somatostatin interneurons enforce layer specific control. eLife 8:e34696. doi: 10.7554/eLife.43696

Nassel, D. R. (2009). Neuropeptide signaling near and far: how localized and timed is the action of neuropeptides in brain circuits? Invert. Neurosci. 9, 57–75. doi: 10.1007/s10117-009-0090-1

Nemeroff, C. B., Widerlov, E., Bissette, G., Wu, Z., Song, K., Zhang, S., Li, Y., and Xu, M. (2020). Regulation of sleep and peripheral pain treatment. *Science* 369:eabb0556. doi: 10.1126/science.aabb0556

Pert, C. B., Pert, A., Chang, J. K., and Fong, B. T. (1976). (D-Ala2)-Met-enkephalinamide: a potent, long-lasting synthetic pentapeptide analgesic. *Science* 194, 330–332. doi: 10.1126/science.968485

Pfeiffer, A., Braun, S., Mann, K., Meyer, H. D., and Brantl, V. (1986). Anterior pituitary hormone responses to a kappa-opioid agonist in man. *J. Clin. Endocrinol. Metab.* 62, 181–185. doi: 10.1210/jcem-62-1-181

Pina, M. M., Patti, D., Hwa, L. S., Wu, S. Y., Mahoney, A. A., Omenyi, C. G., et al. (2020). The kappa opioid receptor modulates GABA neuron excitability and synaptic transmission in midbrainprojections from the insular cortex. *Neuropsychopharmacology* 165:107831. doi: 10.1007/journal.pre pharm.2019.107831

Poras, H., Bonnard, E., Dange, E., Fournie-Zaluski, M. C., and Roques, B. P. (2014). New orally active dual enkephalinase inhibitors (DENKIs) for central and peripheral pain treatment. *J. Med. Chem.* 57, 5748–5763. doi: 10.1021/ jmc500620h

Poyner, D., Cox, H., Bushfield, M., Treherne, J. M., and Demetrakopoulos, M. K. (2000). Neuropeptides in drug research. *Prog. Drug Res.* 54, 121–149. doi: 10.1007/978-3-0348-8391-7_4

Pradayrol, L., Jornvall, H., Mutt, V., and Ribet, A. (1980). N-terminally extended somatostatin: the primary structure of somatostatin-28. *FEBS Lett.* 109, 55–58. doi: 10.1016/0167-4838(80)91130-x

Qian, J., Colmers, W. F., and Saggu, P. (1997). Inhibition of synaptic transmission by neuropeptide Y in rat hippocampal area CA1: modulation of presynaptic Ca2+ entry. *J. Neurosci.* 17, 8169–8177. doi: 10.1523/JNEUROSCI.17-21-08169.1997

Reich, S. E., van Heemkhuize, J. J., Lucassen, P. J., Hoogendijk, W. J., Velders, F. J., and Swaab, D. F. (1995). Corticosterone-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer’s disease and depression. *Am. J. Psychiatry* 152, 1372–1376. doi: 10.1176/ajp.152.9.1372

Rast, D., Brodin, E., Weber, G., and Lindefors, N. (2001). Delayed stress-induced increase in tissue level of cholecystokinin in rat prefrontal cortex modulation by midodralin probe implantation and systemic ketamine. *Brain Res.* 908, 197–203. doi: 10.1016/s0006-8993(01)02648-8

Rajput, P. S., Kharmate, G., Norman, M., Liu, S. H., Sastry, B. R., Bruniciardi, C. F., et al. (2011). Somatostatin receptor 1 and 5 double knockout mice mimic neurochemical changes of Huntington’s disease transgenic mice. *PLoS One* 6:e24467. doi: 10.1371/journal.pone.0024467

Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., and Zhang, F. (2013). Genome engineering using the CRISPR-Cas9 system. *Nat. Protoc.* 8, 2281–2308. doi: 10.1038/nprot.2013.143

Rangon, C. M., Goursaud, S., Medja, F., Lelièvre, V., Mounien, L., Husson, L., et al. (2005). VPAC2 receptors mediate vasoactive intestinal peptide-induced neuroprotection against neonatal excitotoxic brain lesions in mice. *J. Pharmacol. Exp. Ther.* 314, 745–752. doi: 10.1124/jpet.105.086405

Refojo, D., Echenique, C., Müller, M. B., Reul, J. M., Deussing, J. M., Wurst, W., et al. (2005). Corticosterone-releasing hormone activates ERK1/2 MAPK in specific brain areas. *Proc. Natl. Acad. Sci. U.S.A.* 102, 6183–6188. doi: 10.1073/pnas.0502070102

Reinkainen, K. J., Koponen, H., Jolkkonen, J., and Riekkinen, P. J. (1990). Decreased somatostatin-like immunoreactivity in the cerebrospinal fluid of chronic schizophrenic patients with cognitive impairment. *Psychiatry Res.* 37, 307–312. doi: 10.1016/0165-1781(90)90047-9

Reisi, P., Ghadadami, A. R., Golbidi, M., Shahbran, M., Arabpoor, Z., and Rashidi, B. (2015). Effect of cholecystokinin on learning and memory, neuronal proliferation and apoptosis in the rat hippocampus. *Adv. Biomed. Res.* 4:227. doi: 10.4103/2277-9175.134650

Reisine, T., and Bell, G. I. (1995). Molecular biology of somatostatin receptors. *Endocr. Rev.* 16, 427–442. doi: 10.1210/edrv-16-4-427

Robbins, R. J., and Landon, R. M. (1985). The effects of neurotensin, vasoactive intestinal polypeptide and other neuropeptides on the secretion of somatostatin from cerebral cortical cells. *Brain Res.* 332, 161–164. doi: 10.1016/0006-8993(85)90400-7

Roberts, J. G., and Sombers, L. A. (2018). Fast-scan cyclic voltammetry: chemical sensing in the brain and beyond. *Anat. Chem.* 90, 490–504. doi: 10.1021/acs. anat.7b04732

Robich, M. P., Matyal, R., Chu, L. M., Feng, J., Xu, S.-H., Laham, R. J., et al. (2010). Effects of neuropeptide Y on collateral development in a swine model of chronic myocardial ischemia. *J. Mol. Cell. Cardiol.* 49, 1022–1030. doi: 10.1016/j.yjmcc.2010.08.022
Rosenbaum, D. M., Rasmussen, S. G., and Kobila, B. K. (2009). The structure and function of G-protein-coupled receptors. *Nature* 459, 356–363. doi: 10.1038/nature08144

Roth, B. L. (1993). Molecular pharmacology of metabotropic receptors targeted by neuropsychiatric drugs. *Nat. Struct. Mol. Biol.* 26, 533–544. doi: 10.1038/34128

Roy, A., and Pandey, S. C. (2002). The decreased cellular expression of neuropeptide Y protein in rat brain structures during ethanol withdrawal after chronic ethanol exposure. *Alcohol. Clin. Exp. Res.* 26, 796–803. doi: 10.1097/ 00000374-200206000-00008

Rubinow, D. R., Gold, P. W., Post, R. M., and Ballenger, J. C. (1985). *Science* 228, 1184–1194. doi: 10.1126/science.3861934

Rubinow, D. R., Gold, P. W., Post, R. M., and Ballenger, J. C. (1985). *Science* 228, 1184–1194. doi: 10.1126/science.3861934

Senese, N. B., Kandasamy, R., Kochan, K. E., and Traynor, J. R. (2020). Regulator Frontiers in Neural Circuits | www.frontiersin.org 715–721. doi: 10.1016/j.brainres.2020.02.012

Siegel, R. A., Duker, E. M., Fuchs, E., Pahnke, U., and Wuttke, W. (1984). Responsiveness of mesolimbic, mesocortical, septal and hippocampal cholecystokinin and substance P neuronal systems to stress, in the male rat. *Neurochem. Int.* 6, 783–789. doi: 10.1016/0197-0186(84)90011-1

Silberman, Y., Bajo, M., Chappell, A. M., Christian, D. T., Cruz, M., Diaz, M. R., et al. (2009). Neurobiological mechanisms contributing to alcohol-stress anxiety interactions. *Alcohol. 43, 509–519. doi: 10.1016/j.alcohol.2009.01. 002

Sirohi, S., and Walker, B. M. (2015). Maturational alterations in constitutive activity of medial prefrontal cortex kappa-opioid receptors in Wistar rats. *J. Neurochem.* 135, 659–665. doi: 10.1111/jnc.13279

Slater, P. G., Cerda, C. A., Pereira, L. A., Andres, M. E., and Gysling, K. (2016). CRF binding protein facilitates the presence of CRF type 2 alpha receptor on the cell surface. *Proc. Natl. Acad. Sci. U.S.A.* 113, 4075–4080. doi: 10.1073/pnas. 1523745113

Smialowska, M., Zieba, B., and Domini, H. (2021). A role of noradrenergic receptors in anxiolytic-like effect of high CRF in the rat frontal cortex. *Neuropediatrics* 88:102162. doi: 10.1016/j.np.2021.102162

Smith, S. J., Sumbul, U., Graybuck, L. T., Collman, F., Seshamani, S., Gala, R., et al. (2019). Single-cell transcriptomic evidence for dense intracortical neuropeptide networks. *eLife* 8:e47889. doi: 10.7554/eLife.47889

Smith, A. J., and Palmer, R. D. (2018). Detecting and avoiding problems when using the Cre-lox system. *Trends Genet.* 34, 333–340. doi: 10.1016/j.tig.2017. 12.008

Song, Y. H., Hwang, Y. S., Kim, L. E., Lee, H. R., Kim, J. H., Malachlan, C., et al. (2020). Somatostatin enhances visual processing and perception by suppressing excitatory inputs to parvalbumin-positive interneurons in V1. *Sci. Adv.* eaax0517. doi: 10.1126/sciadv.aax0517

Song, Y. H., Yoon, J., and Lee, S. H. (2021). The role of neuropeptide somatostatin in the brain and its application in treating neurological disorders. *Exp. Mol. Med.* 53, 328–338. doi: 10.1038/s41227-021-00580-4

Spetea, M., Asim, M. F., Wolber, G., and Schmidhammer, H. (2013). The micro opioid receptor and ligands acting at the micro opioid receptor, as therapeutics and potential therapeutics. *Curr. Pharm. Des.* 19, 7415–7434. doi: 10.2174/1381612131319990362

Spreierling, S. R., and Zorrilla, E. P. (2017). Don’t stress about CRF: assessing the translational failures of CRF1 antagonists. *Psychopharmacology* 234, 1467–1481. doi: 10.1007/s00213-017-4749-2

Stengel, A., and Tache, Y. F. (2017). Activation of brain somatostatin signaling suppresses CRF receptor-mediated stress response. *Front. Neurosci.* 11:231. doi: 10.3389/fnins.2017.00231

Stoeber, M., Jullie, D., Lobingier, B. T., Laeremans, T., Steyaert, J., Schiller, P. W., et al. (2018). A genetically encoded biosensor reveals location bias of opioid drug action. *Neuron* 98, 963.e5–976.e5. doi: 10.1016/j.neuron.2018.04.021

Sudhof, T. C. (2012). Calcium control of neurotransmitter release. *Cold Spring Harb. Perspect. Biol.* 4:a011353. doi: 10.1101/cshperspect.a011353

Sun, H., Luessen, D. I., Kind, K. O., Zhang, K., and Chen, R. (2020). Cocaine self-administration regulates transcription of opioid peptide precursors and opioid receptors in rat caudate putamen and prefrontal cortex. *Neuroscience* 43, 131–139. doi: 10.1016/j.neuroscience.2020.07.035

Sun, Q. Q., Akk, G., Huguenard, J. R., and Prince, D. A. (2001). Differential regulation of GABA release and neuronal excitability mediated by neuropeptide Y1 and Y2 receptors in rat thalamic neurons. *J. Physiol.* 531, 81–94. doi: 10.1111/j.1469-7793.2001.00811.x

Svingos, A. L., and Colago, E. E. (2002). Kappa-Opioid and NMDA glutamate receptors are differentially targeted within rat medial prefrontal cortex. *Brain Res.* 946, 262–271. doi: 10.1016/s0006-8993(02)02089-4

Svingos, A. L., Colago, E. E., and Pickel, V. M. (1999). Cellular sites for dynorphin activation of kappa-opioid receptors in the rat nucleus accumbens shell. *J. Neurosci.* 19, 1804–1813. doi: 10.1016/S0022-5142(10)83642-X

Takahashi, A. (2016). “Subchapter 7A - enkephalin,” in *Handbook of Hormones, eds H. A. Yoshio Takei and K. Tsutsui (Cambridge, MA: Academic Press), 55–57.
Taussig, R., Iniguez-Lluhi, J. A., and Gilman, A. G. (1993). Inhibition of Tasic, B., Yao, Z., Graybuck, L. T., Smith, K. A., Nguyen, T. N., Bertagnolli, D., et al. Taqi, M. M., Bazov, I., Watanabe, H., Sheedy, D., Harper, C., Alkass, K., et al. Tejeda, H. A., Wang, H., Flores, R. J., and Yarur, H. E. (2021). Dynorphin/kappa-opioid receptor system modulation of cortical circuitry. J. Neurochem. 98, 217–221. doi: 10.3389/fncel.2020.00284-Tremblay, R., Lee, S., and Rudy, B. (2016). GABAergic interneurons in the neoncortex: from cellular properties to circuits. Neuron 91, 260–292. doi: 10.1016/j.neuron.2016.06.033

Trieru, B. H., Remmers, B. C., Toddes, C., Brandner, D. D., Lefevre, E. M., Kocharian, A., et al. (2022). Angiotensin-converting enzyme gates brain circuit-specific plasticity via an endogenous opioid. Science 375, 1177–1182. doi: 10.1126/science.abl5310

Tripp, A., Kota, R. S., Lewis, D. A., and Sibille, E. (2011). Reduced somatostatin in subgenual anterior cingulate cortex in major depression. Neuropsychol. Dis. 42, 116–124. doi: 10.1080/18765179.2011.576431

Truitt, W. A., Johnson, P. L., Dietrich, A. D., Fitz, S. D., and Shekhaw, A. (2009). Anxiety-like behavior is modulated by a discrete subpopulation of interneurons in the basolateral amygudala. Neuroscience 160, 284–294. doi: 10.1016/j.neuroscience.2009.01.083

Ungless, M. A., Singh, V., Crowder, T. L., Yaka, R., Ron, D., and Bonci, A. (2003). Corticotropin-releasing factor requires CRF binding protein to potentiate NMDA receptors via CRF receptor 2 in dopamine neurons. Neuron 39, 401–407. doi: 10.1016/S0896-6273(03)00461-6

Urban-Ciecko, J., and Barth, A. L. (2016). Somatostatin-expressing neurons in cortical networks. Nat. Rev. Neurosci. 17, 401–409. doi: 10.1038/nrn.2016.53

Uribe-Marino, A., Gassen, N. C., Wiesbeck, M. F., Balsevich, G., Santarelli, S., Solfrank, B., et al. (2016). Prefrontal cortical corticotropin-releasing factor receptor 1 conveys acute stress-induced executive dysfunction. Biol. Psychiatry 80, 743–753. doi: 10.1016/j.biopsych.2016.03.2106

Vale, W., Spiess, J., Rivier, C., and Rivier, J. (1981). Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213, 1394–1397. doi: 10.1126/science.6276999

van den Pol, A. N. (2012). Neuropeptide transmission in brain circuits. Neuron 76, 98–115. doi: 10.1016/j.neuron.2012.09.014

Van Pett, K., Vivia, V., Bittencourt, J. C., Chan, R. K., Li, H. Y., Arias, C., et al. (2000). Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J. Comp. Neurol. 428, 191–212. doi: 10.1006/jcn.2000.2123

Vezzani, A., and Sperk, G. (2004). Overexpression of NPY and Y2 receptors in epileptic brain tissue: an endogenous neuroprotective mechanism in temporal lobe epilepsy? Neuropeptides 38, 245–252. doi: 10.1016/j.npep.2004.05.004

Vollmer, L. L., Schmelter, S., Schurjak, D., Ahlbrand, R., Rush, J., Dolgas, C. M., et al. (2016). Neuropeptide Y impairs retrieval of extinguished fear and modulates excitability of neurons in the infralimbic prefrontal cortex. J. Neurosci. 36, 1306–1315. doi: 10.1523/JNEUROSCI.4955-13.2016

Wagner, J. J., Evans, C. J., and Chavkin, C. (1991). Focal stimulation of the mossy fibers releases endogenous dynorphins that bind kappa 1-opioid receptors in guinea pig hippocampus. J. Neurochem. 57, 333–343. doi: 10.1111/j.1471-4159.1991.tb01232.x

Wall, P. M., Flinn, J., and Messier, C. (2001). Infralimbic muscaminic M1 receptors modulate anxiety-like behaviour and spontaneous working memory in mice. Psychopharmacology 155, 58–68. doi: 10.1007/s002130000671

Wall, P. M., and Messier, C. (2002). Infralimbic kappa opioid and muscarinic M1 receptor interactions in the concurrent modulation of anxiety and memory. Psychopharmacology 160, 233–244. doi: 10.1007/s00213-001-0979-9

Wang, H., Jing, M., and Li, Y. (2018). Lighting up the brain: genetically encoded fluorescent sensors for imaging neurotransmitters and neuromodulators. Curr. Opin. Neurobiol. 50, 171–178. doi: 10.1016/j.conb.2018.03.010

Wang, H. L., Bogen, C., Reisine, T., and Dichter, M. (1989). Somatostatin-14 and somatostatin-28 induce opposite effects on potassium currents in rat neocortical neurons. Proc. Natl. Acad. Sci. U.S.A. 86, 9616–9620. doi: 10.1073/pnas.86.25.9616

Wang, J., Tian, Y., Zeng, L. H., and Xu, H. (2020). Prefrontal disinhibition in social fear: a vital action of somatostatin interneurons. Front Cell Neurosci. 14:011732. doi: 10.3389/fncel.2020.611732

Wang, J.-Y., Yaksi, T. L., and Go, V. L. (1985). Studies on the in vivo release of vasoactive intestinal polypeptide (VIP) from the cerebral cortex: effects of

Frontiers in Neural Circuits | www.frontiersin.org 29 June 2022 | Volume 16 | Article 796443
Willoch, F., Schindler, F., Wester, H. J., Empl, M., Straube, A., Schwaiger, M., Williams, J. A., Sans, M. D., Tashiro, M., Schäfer, C., Bragado, M. J., and Widdowson, P. S., Ordway, G. A., and Halaris, A. E. (1992). Reduced neuropeptide

Wood, D. E., and Nusbaum, M. P. (2002). Extracellular peptidase activity

Wingler, L. M., and Lefkowitz, R. J. (2020). Conformational basis of G protein-

Wang, J. Y., Yaksh, T. L., Harty, G. J., and Go, V. L. (1986). Neurotransmitter

Yakovleva, T., Bazov, I., Cebers, G., Marinova, Z., Hara, Y., Ahmed, A., et al. (2006). Genetic variation in human NPY expression affects stress response and emotion. Nature 452, 997–1001. doi: 10.1038/nature06858

Zieba, B., Grzegorzewska, M., Branski, P., Domin, H., Wieronska, J. M., Hess, G., et al. (2008). The behavioural and electrophysiological effects of CRF in rat frontal cortex. Neuroendocrinology 42, 513–523. doi: 10.1006/j.endo.2008.05.004

Zobel, A. W., Nickel, T., Kunzel, H. E., Ackl, N., Sonntag, A., Ising, M., et al. (2009). Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. 43, 171–181. doi: 10.1016/j.jpsychires.2008.08.006

Zorrilla, E. P., Logrip, M. L., and Koob, G. F. (2014). Corticotropin releasing factor: a key role in the neurobiology of addiction. Front. Neuroendocrinol. 35, 234–244. doi: 10.1016/j.yfrne.2014.01.001

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Casello, Flores, Yarur, Wang, Awanyai, Arenivar, Jaime-Lara, Bravo-Rivera and Tejeda. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.